US7838216B1
(en)
*
|
1986-03-05 |
2010-11-23 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Human gene related to but distinct from EGF receptor gene
|
US5869620A
(en)
*
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US20050058638A1
(en)
*
|
1987-05-21 |
2005-03-17 |
Huston James S. |
Biosynthetic binding proteins for immuno-targeting
|
JP2919890B2
(ja)
*
|
1988-11-11 |
1999-07-19 |
メディカル リサーチ カウンスル |
単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
|
WO1992015682A1
(en)
*
|
1991-02-27 |
1992-09-17 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
JPH06510529A
(ja)
*
|
1991-08-05 |
1994-11-24 |
イゲン,インコーポレーテッド |
目標とする触媒性たんぱく質により活性化されるプロドラッグ
|
US6025165A
(en)
*
|
1991-11-25 |
2000-02-15 |
Enzon, Inc. |
Methods for producing multivalent antigen-binding proteins
|
US20070031931A1
(en)
*
|
1992-02-06 |
2007-02-08 |
Chiron Corporation |
Biosynthetic binding proteins for immuno-targeting
|
EP1997894B1
(de)
*
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetisches Bindeprotein für Tumormarker
|
US7754211B2
(en)
*
|
1992-04-10 |
2010-07-13 |
Research Development Foundation |
Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
|
US20080152586A1
(en)
*
|
1992-09-25 |
2008-06-26 |
Avipep Pty Limited |
High avidity polyvalent and polyspecific reagents
|
WO1994012520A1
(en)
*
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
DK0672142T3
(da)
*
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
ATE173740T1
(de)
|
1993-09-22 |
1998-12-15 |
Medical Res Council |
Antikoerper mit geaenderter zielrichtung
|
US5753225A
(en)
|
1993-12-03 |
1998-05-19 |
The Regents Of The University Of California |
Antibodies that mimic actions of neurotrophins
|
IT1264083B1
(it)
*
|
1993-12-10 |
1996-09-10 |
Enea Ente Nuove Tec |
Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
|
US5763733A
(en)
*
|
1994-10-13 |
1998-06-09 |
Enzon, Inc. |
Antigen-binding fusion proteins
|
US6514942B1
(en)
*
|
1995-03-14 |
2003-02-04 |
The Board Of Regents, The University Of Texas System |
Methods and compositions for stimulating T-lymphocytes
|
AUPO591797A0
(en)
*
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
*
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
DK0896586T4
(en)
*
|
1996-03-27 |
2015-08-24 |
Genentech Inc |
ErbB3 antibodies.
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
ATE465257T1
(de)
*
|
1996-07-03 |
2010-05-15 |
Genentech Inc |
Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
|
JP4219985B2
(ja)
*
|
1996-07-23 |
2009-02-04 |
タノックス ファーマ ベスローテン フェンノートシャップ |
二つの共刺激経路を同時にブロックできる可溶性分子を用いたt細胞寛容の誘導
|
JP2000516808A
(ja)
*
|
1996-08-05 |
2000-12-19 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Mhc結合ペプチドオリゴマーおよび使用方法
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
US6013632A
(en)
*
|
1997-01-13 |
2000-01-11 |
Emory University |
Compounds and their combinations for the treatment of influenza infection
|
WO1998033809A1
(en)
*
|
1997-01-31 |
1998-08-06 |
The General Hospital Corporation |
Compositions and methods for imaging gene expression
|
US20030109680A1
(en)
*
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20060235209A9
(en)
*
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
US5986065A
(en)
*
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US7749498B2
(en)
*
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
WO1998048837A1
(en)
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
AU735883C
(en)
|
1997-06-13 |
2002-02-07 |
Genentech Inc. |
Protein recovery by chromatography followed by filtration upon a charged layer
|
US6172213B1
(en)
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US5994511A
(en)
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
FR2766826B1
(fr)
*
|
1997-08-04 |
2001-05-18 |
Pasteur Institut |
Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
|
US6737249B1
(en)
*
|
1997-08-22 |
2004-05-18 |
Genentech, Inc. |
Agonist antibodies
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
EP1947119A3
(de)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
|
EP1941905A1
(de)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
WO1999061057A2
(en)
*
|
1998-05-23 |
1999-12-02 |
Tanox, Inc. |
Molecules targeting cd40 and tumor cells
|
GB9812545D0
(en)
*
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
US7405320B2
(en)
|
1998-06-22 |
2008-07-29 |
Immunomedics, Inc. |
Therapeutic and diagnostic conjugates for use with multispecific antibodies
|
US7833528B2
(en)
*
|
1998-06-22 |
2010-11-16 |
Immunomedics, Inc. |
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
|
US7138103B2
(en)
*
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
US6962702B2
(en)
*
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
DE69942148D1
(de)
*
|
1998-06-22 |
2010-04-29 |
Immunomedics Inc |
Gebrauch von bispezifischen antikörpern in diagnose und therapie
|
US7387772B1
(en)
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
DE19831429A1
(de)
*
|
1998-07-07 |
2000-04-27 |
Jerini Biotools Gmbh |
Verfahren zur Identifizierung und chemisch-synthetischen Nachahmung von Bindungsstellen auf Proteinen
|
US6228360B1
(en)
*
|
1998-08-19 |
2001-05-08 |
Ajinomoto Co., Inc. |
Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
|
US7067144B2
(en)
*
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US6818749B1
(en)
*
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
WO2000029431A1
(en)
*
|
1998-11-17 |
2000-05-25 |
Tanox, Inc. |
Bispecific molecules cross-linking itim and itam for therapy
|
US7118743B2
(en)
|
1998-11-17 |
2006-10-10 |
Tanox, Inc. |
Bispecific molecules cross-linking ITIM and ITAM for therapy
|
EP1950300A3
(de)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
|
CA2727172A1
(en)
|
1999-05-26 |
2001-01-04 |
Genentech, Inc. |
Methods of treatment using anti-erbb antibody-maytansinoid conjugates
|
BRPI0017590B8
(pt)
|
1999-06-25 |
2021-05-25 |
Genentech Inc |
conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
DE60033658T2
(de)
*
|
1999-06-25 |
2007-11-22 |
Genentech, Inc., South San Francisco |
Behandlung von prostata-krebs mit anti-erbb2 antikörpern
|
KR20090126330A
(ko)
|
1999-08-27 |
2009-12-08 |
제넨테크, 인크. |
항-ErbB2 항체 투여 치료 방법
|
EP2266607A3
(de)
|
1999-10-01 |
2011-04-20 |
Immunogen, Inc. |
Immunokonjugate für Krebsbehandlung
|
US6794494B1
(en)
*
|
2003-04-14 |
2004-09-21 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
AU3662101A
(en)
*
|
2000-02-01 |
2001-08-14 |
Tanox Inc |
Cd40-binding apc-activating molecules
|
WO2001062800A1
(en)
*
|
2000-02-24 |
2001-08-30 |
Eidgenössische Technische Hochschule Zürich |
Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
|
US6319694B1
(en)
*
|
2000-03-03 |
2001-11-20 |
Genopsys, Inc. |
Random truncation and amplification of nucleic acid
|
US7097840B2
(en)
*
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
EP1284752A4
(de)
*
|
2000-04-26 |
2004-08-18 |
Elusys Therapeutics Inc |
Biospezifische moleküle und deren verwendung
|
EP1280923A2
(de)
*
|
2000-04-28 |
2003-02-05 |
Millennium Pharmaceuticals, Inc. |
14094, ein angehörige der menschlichen trypsin-familie, und dessen verwendungen
|
PL400669A1
(pl)
*
|
2000-05-19 |
2012-11-05 |
Genentech, Inc. |
Genowa próba wykrywania odpowiedzi na antagoniste ErbB dla poprawienia prawdopodobienstwa i skutecznosci leczenia raka
|
JP2003534022A
(ja)
*
|
2000-05-26 |
2003-11-18 |
スミスクライン・ビーチャム・コーポレイション |
Rankリガンド介在障害の治療に有用な抗−rankリガンドモノクローナル抗体
|
WO2001097858A2
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
GB0027328D0
(en)
*
|
2000-06-23 |
2000-12-27 |
Aventis Pharma Inc |
Bioengineered vehicles for targeted nucleic acid delivery
|
JP2004529848A
(ja)
*
|
2000-09-07 |
2004-09-30 |
シエーリング アクチエンゲゼルシャフト |
EDb−フィブロネクチンドメイン(II)の受容体
|
US6631283B2
(en)
*
|
2000-11-15 |
2003-10-07 |
Virginia Tech Intellectual Properties, Inc. |
B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging
|
KR100830082B1
(ko)
*
|
2001-01-05 |
2008-05-20 |
화이자 인크. |
인슐린 유사 성장 인자 ι수용체에 대한 항체
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
PT1381384E
(pt)
|
2001-04-24 |
2011-09-01 |
Merck Patent Gmbh |
Terapia de combinação usando agentes anti-angiogénicos e tnfa
|
CN1195779C
(zh)
*
|
2001-05-24 |
2005-04-06 |
中国科学院遗传与发育生物学研究所 |
抗人卵巢癌抗人cd3双特异性抗体
|
US20060270003A1
(en)
|
2003-07-08 |
2006-11-30 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
WO2003000113A2
(en)
|
2001-06-20 |
2003-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US6995171B2
(en)
|
2001-06-21 |
2006-02-07 |
Agouron Pharmaceuticals, Inc. |
Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
|
EP1487877B1
(de)
|
2001-09-18 |
2010-10-27 |
Genentech, Inc. |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20030228319A1
(en)
|
2002-04-16 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AR039067A1
(es)
*
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
JP2005525095A
(ja)
|
2002-01-02 |
2005-08-25 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
MXPA04006517A
(es)
*
|
2002-01-03 |
2005-03-31 |
Schering Ag |
Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
|
US6870034B2
(en)
|
2002-02-05 |
2005-03-22 |
Genentech, Inc. |
Protein purification
|
US6869787B2
(en)
*
|
2002-02-27 |
2005-03-22 |
The United States Of America As Represented By The Secretary Of The Army |
Ricin vaccine and methods of making and using thereof
|
JP2005522514A
(ja)
|
2002-04-10 |
2005-07-28 |
ジェネンテック・インコーポレーテッド |
抗her2抗体改変体
|
MXPA04009809A
(es)
*
|
2002-04-11 |
2004-12-13 |
Amgen Inc |
Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas.
|
UA77303C2
(en)
*
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
AU2003248744C1
(en)
*
|
2002-06-28 |
2009-12-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors
|
CN101711866A
(zh)
|
2002-07-15 |
2010-05-26 |
健泰科生物技术公司 |
鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
|
EP3388452A3
(de)
|
2002-09-11 |
2019-02-20 |
Genentech, Inc. |
Proteinreinigung
|
AU2002951853A0
(en)
*
|
2002-10-04 |
2002-10-24 |
Commonwealth Scientific And Industrial Research Organisation |
Crystal structure of erbb2 and uses thereof
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
US20040258685A1
(en)
*
|
2002-11-21 |
2004-12-23 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
CN1747950A
(zh)
*
|
2002-12-19 |
2006-03-15 |
美国辉瑞有限公司 |
用于治疗眼病的作为蛋白激酶抑制剂的2-(1h-吲唑-6-基氨基)-苯甲酰胺化合物
|
EP2407485B1
(de)
|
2003-02-01 |
2016-01-27 |
Tanox, Inc. |
Hochaffine Antikörper gegen menschliches IgE
|
EA010727B1
(ru)
|
2003-02-26 |
2008-10-30 |
Суджен, Инк. |
Аминогетероарильные соединения в качестве ингибиторов протеинкиназ
|
KR20050119671A
(ko)
*
|
2003-04-03 |
2005-12-21 |
화이자 인코포레이티드 |
Ag013736을 포함하는 제형
|
LT2335725T
(lt)
|
2003-04-04 |
2017-01-25 |
Genentech, Inc. |
Didelės koncentracijos antikūno ir baltymo kompozicijos
|
WO2004091657A2
(en)
|
2003-04-09 |
2004-10-28 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
|
US7425328B2
(en)
*
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
KR20120104408A
(ko)
|
2003-05-30 |
2012-09-20 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
PT1631313E
(pt)
|
2003-06-05 |
2015-07-02 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
ES2527102T3
(es)
*
|
2003-06-19 |
2015-01-20 |
Genentech, Inc. |
Composiciones y métodos para el tratamiento de trastornos relacionados con la coagulación
|
AU2004265253B2
(en)
|
2003-07-28 |
2011-09-01 |
Genentech, Inc. |
Reducing protein A leaching during protein A affinity chromatography
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
US7589181B2
(en)
*
|
2003-08-29 |
2009-09-15 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
|
WO2005021553A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Pfizer Inc. |
Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
|
DE602004017479D1
(de)
*
|
2003-08-29 |
2008-12-11 |
Pfizer |
Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
|
AR045563A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
SI2295073T1
(sl)
|
2003-11-17 |
2014-07-31 |
Genentech, Inc. |
Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
|
JP4864719B2
(ja)
*
|
2003-11-26 |
2012-02-01 |
ファイザー・プロダクツ・インク |
Gsk−3インヒビターとしてのアミノピラゾール誘導体
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
DK1716181T3
(da)
|
2004-02-19 |
2010-03-01 |
Genentech Inc |
CDR-reparerede antistoffer
|
WO2006074418A2
(en)
|
2005-01-07 |
2006-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
CA2561516A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
JP5128935B2
(ja)
|
2004-03-31 |
2013-01-23 |
ジェネンテック, インコーポレイテッド |
ヒト化抗TGF−β抗体
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
NZ579482A
(en)
|
2004-06-01 |
2011-02-25 |
Genentech Inc |
Antibody drug conjugates and methods
|
ZA200610158B
(en)
|
2004-06-04 |
2008-07-30 |
Genentech Inc |
Method for treating multiple sclerosis
|
SV2006002143A
(es)
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
NZ552091A
(en)
*
|
2004-07-16 |
2009-09-25 |
Pfizer Prod Inc |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
EP1771474B1
(de)
|
2004-07-20 |
2010-01-27 |
Genentech, Inc. |
Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
|
CN101018780B
(zh)
*
|
2004-08-26 |
2012-01-11 |
辉瑞大药厂 |
作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物
|
CA2578075A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
|
CA2578066C
(en)
*
|
2004-08-26 |
2011-10-11 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
ATE432469T1
(de)
*
|
2004-09-21 |
2009-06-15 |
Us Gov Health & Human Serv |
Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US20060107555A1
(en)
*
|
2004-11-09 |
2006-05-25 |
Curtis Marc D |
Universal snow plow adapter
|
PL1846030T3
(pl)
|
2005-01-21 |
2019-05-31 |
Genentech Inc |
Ustalone dawkowanie przeciwciał her
|
RU2007133660A
(ru)
*
|
2005-02-09 |
2009-03-20 |
Дженентек, Инк. (Us) |
Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы
|
CA2597924C
(en)
|
2005-02-15 |
2018-10-02 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
MX2007009889A
(es)
|
2005-02-23 |
2007-09-07 |
Genentech Inc |
Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer.
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
EP1863848A4
(de)
|
2005-03-31 |
2009-09-23 |
Agensys Inc |
An 161p2f10b-proteine bindende antikörper und verwandte moleküle
|
EP2444419A1
(de)
|
2005-04-26 |
2012-04-25 |
Pfizer Inc. |
P-Cadherin-Antikörper
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
JP2008541781A
(ja)
|
2005-06-06 |
2008-11-27 |
ジェネンテック・インコーポレーテッド |
異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
|
US8343928B2
(en)
|
2005-07-07 |
2013-01-01 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
|
EP1995321A2
(de)
|
2005-08-15 |
2008-11-26 |
Genentech, Inc. |
Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
|
JP5161777B2
(ja)
|
2005-09-07 |
2013-03-13 |
アムジェン フレモント インク. |
アクチビン受容体様キナーゼ−1に対するヒトモノクローナル抗体
|
WO2007035744A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
DK2500030T4
(en)
|
2005-11-04 |
2018-10-29 |
Genentech Inc |
Use of complement pathway inhibitors for the treatment of eye diseases
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
AU2006335053A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
JP2009518314A
(ja)
|
2005-12-02 |
2009-05-07 |
ジェネンテック・インコーポレーテッド |
Il−22に結合する抗体およびil−22rに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
|
US7763245B2
(en)
|
2005-12-15 |
2010-07-27 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
US7625759B2
(en)
|
2005-12-19 |
2009-12-01 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
WO2007130697A2
(en)
|
2006-01-05 |
2007-11-15 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using same
|
WO2007112146A2
(en)
*
|
2006-01-13 |
2007-10-04 |
Irm Llc |
Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
|
AU2007207465B2
(en)
|
2006-01-18 |
2012-12-06 |
Merck Patent Gmbh |
Specific therapy using integrin ligands for treating cancer
|
CA2638821A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
JP2009531324A
(ja)
|
2006-03-20 |
2009-09-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
癌標的化のための操作された抗前立腺幹細胞抗原(psca)抗体
|
US20110135570A1
(en)
|
2006-03-23 |
2011-06-09 |
Mary Jo Janatpour |
Anti-Tumor Cell Antigen Antibody Therapeutics
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
UA91129C2
(ru)
|
2006-05-09 |
2010-06-25 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
|
NL2000613C2
(nl)
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazoolpyrazinederivaten.
|
ES2567402T3
(es)
|
2006-05-30 |
2016-04-22 |
Genentech, Inc. |
Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
|
PT2027156E
(pt)
|
2006-06-02 |
2011-04-18 |
Aveo Pharmaceuticals Inc |
Proteínas de ligação ao factor de crescimento de hepatócito (hgf)
|
AR061170A1
(es)
|
2006-06-02 |
2008-08-06 |
Aveo Pharmaceuticals Inc |
Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
KR101513498B1
(ko)
|
2006-06-30 |
2015-04-21 |
노보 노르디스크 에이/에스 |
항―nkg2a 항체 및 이들의 용도
|
WO2008011081A2
(en)
|
2006-07-19 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
Wsx-1/p28 as a target for anti-inflammatory responses
|
US7862813B2
(en)
|
2006-07-29 |
2011-01-04 |
Bjork Jr Robert Lamar |
Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
|
CA2660286A1
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
WO2008023840A2
(en)
|
2006-08-25 |
2008-02-28 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
PL2066349T3
(pl)
|
2006-09-08 |
2012-09-28 |
Medimmune Llc |
Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
|
US9012162B2
(en)
|
2006-09-08 |
2015-04-21 |
The Chancellor, Masters And Scholars Of The University Of Oxford |
Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
|
WO2011008990A1
(en)
|
2009-07-15 |
2011-01-20 |
Prometheus Laboratories Inc. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
RS53942B1
(en)
|
2006-10-27 |
2015-08-31 |
Genentech Inc. |
Antibodies and Immunoconjugates and Their Use
|
CA2667376A1
(en)
|
2006-11-14 |
2008-05-22 |
Genentech, Inc. |
Modulators of neuronal regeneration
|
CA2670471A1
(en)
|
2006-11-22 |
2008-06-05 |
Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
EP2962697A1
(de)
|
2006-11-27 |
2016-01-06 |
diaDexus, Inc. |
Ovr110-antikörperzusammensetzungen und verfahren zur verwendung
|
TWI419904B
(zh)
|
2006-12-18 |
2013-12-21 |
Genentech Inc |
拮抗劑抗-notch3抗體及其用於預防及治療notch3相關疾病之用途
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
WO2008079280A1
(en)
|
2006-12-21 |
2008-07-03 |
Millipore Corporation |
Purification of proteins
|
CN101605561A
(zh)
*
|
2006-12-22 |
2009-12-16 |
诺韦利克斯治疗有限公司 |
通过至少一种表皮生长因子受体特异性抗体或其衍生物的糖尿病治疗
|
BRPI0806596A2
(pt)
|
2007-01-18 |
2013-07-23 |
Merck Patent Ges Mit Berchraenkter Haftung |
medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
|
MX2009008430A
(es)
|
2007-02-09 |
2009-10-28 |
Genentech Inc |
Anticuerpos anti-robo4 y sus usos.
|
DK2140021T3
(da)
|
2007-02-22 |
2012-05-07 |
Genentech Inc |
Fremgangsmåder til detektion af inflammatorisk tarmsygdom.
|
EP2899541A1
(de)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
AU2008239594B2
(en)
|
2007-04-13 |
2013-10-24 |
Beth Israel Deaconess Medical Center |
Methods for treating cancer resistant to ErbB therapeutics
|
BRPI0811466A2
(pt)
|
2007-05-07 |
2014-10-14 |
Medimmune Llc |
Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
|
WO2008141278A1
(en)
*
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Method for preparing antibody conjugates
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
DK2171090T3
(da)
|
2007-06-08 |
2013-06-10 |
Genentech Inc |
Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
|
US20090053786A1
(en)
|
2007-07-09 |
2009-02-26 |
Yung-Hsiang Kao |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
AU2008276140C1
(en)
|
2007-07-16 |
2021-01-28 |
Genentech, Inc. |
Anti-CD79b antibodies and immunoconjugates and methods of use
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
JP2010536844A
(ja)
|
2007-08-24 |
2010-12-02 |
オンコセラピー・サイエンス株式会社 |
癌の治療標的及び診断マーカーとしてのdkk1癌遺伝子
|
RU2010111116A
(ru)
|
2007-08-24 |
2011-09-27 |
Онкотерапи Сайенс, Инк. (Jp) |
Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы
|
WO2009028580A1
(en)
|
2007-08-24 |
2009-03-05 |
Oncotherapy Science, Inc. |
Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
|
WO2009032661A1
(en)
|
2007-08-29 |
2009-03-12 |
Sanofi-Aventis |
Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
|
JP6126773B2
(ja)
|
2007-09-04 |
2017-05-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原(psca)抗体
|
WO2009033094A2
(en)
|
2007-09-07 |
2009-03-12 |
Agensys, Inc. |
Antibodies and related molecules that bind to 24p4c12 proteins
|
RU2526512C2
(ru)
|
2007-09-26 |
2014-08-20 |
Чугаи Сейяку Кабусики Кайся |
Модифицированная константная область антитела
|
WO2009046123A2
(en)
|
2007-10-02 |
2009-04-09 |
Genentech, Inc. |
Nlrr-1 antagonists and uses thereof
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
EP2200631A1
(de)
|
2007-10-16 |
2010-06-30 |
Zymogenetics, Inc. |
Kombination aus blys-hemmung und anti-cd20-wirkstoffen zur behandlung von autoimmunerkrankungen
|
US20090148435A1
(en)
|
2007-10-30 |
2009-06-11 |
Genentech, Inc. |
Antibody purification by cation exchange chromatography
|
KR101867606B1
(ko)
|
2007-11-07 |
2018-06-18 |
제넨테크, 인크. |
미생물 질환의 치료를 위한 조성물 및 방법
|
AU2008321016B2
(en)
|
2007-11-12 |
2013-03-28 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
AU2008334095A1
(en)
|
2007-11-29 |
2009-06-11 |
Genentech, Inc. |
Gene expression markers for inflammatory bowel disease
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
CA3102704A1
(en)
|
2007-12-14 |
2009-06-25 |
Novo Nordisk A/S |
Antibodies against human nkg2d and uses thereof
|
WO2009086197A1
(en)
|
2007-12-20 |
2009-07-09 |
Monogram Biosciences, Inc. |
Her-2 diagnostic methods
|
US8253725B2
(en)
*
|
2007-12-28 |
2012-08-28 |
St. Jude Medical, Atrial Fibrillation Division, Inc. |
Method and system for generating surface models of geometric structures
|
EP2077281A1
(de)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
CN101952317B
(zh)
|
2008-01-24 |
2015-07-22 |
诺沃-诺迪斯克有限公司 |
人化抗-人nkg2a单克隆抗体
|
EP2238162A1
(de)
*
|
2008-01-24 |
2010-10-13 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Induzierte internalisierung von oberflächenrezeptoren
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
KR101607346B1
(ko)
|
2008-01-31 |
2016-03-29 |
제넨테크, 인크. |
항-cd79b 항체 및 면역접합체 및 사용 방법
|
MX2010008874A
(es)
|
2008-02-14 |
2010-09-22 |
Bristol Myers Squibb Co |
Terapeuticos dirigidos a base de proteinas manipuladas que se unen al receptor de factor de crecimiento epidermico.
|
CA2716826C
(en)
|
2008-02-25 |
2017-05-09 |
Prometheus Laboratories Inc. |
Drug selection for breast cancer therapy using antibody-based arrays
|
CN102015766B
(zh)
|
2008-03-10 |
2014-07-16 |
特罗科隆科学有限公司 |
用于对巨细胞病毒感染进行治疗以及诊断的组合物以及方法
|
EP2638907A3
(de)
|
2008-03-18 |
2014-05-14 |
Genentech, Inc. |
Kombination aus einem Anti-HER2-Antikörperwirkstoffkonjugat und Lapatonib
|
ES2354661B1
(es)
|
2008-05-08 |
2012-02-01 |
Consejo Superior De Investigaciones Científicas (Csic) |
Método para generar anticuerpos monoclonales que reconocen antígenos de membrana de células progenitoras neurales, anticuerpos producidos por dicho método, y usos.
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
AR071874A1
(es)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
US8999702B2
(en)
|
2008-06-11 |
2015-04-07 |
Emd Millipore Corporation |
Stirred tank bioreactor
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
US20100029675A1
(en)
*
|
2008-07-25 |
2010-02-04 |
Hwang Soo-In |
Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
|
RS59232B1
(sr)
|
2008-08-14 |
2019-10-31 |
Genentech Inc |
Postupci za uklanjanje zagađivača koristeći hromatografiju membrane razmene jona sa razmeštanjem autohtonih proteina
|
ES2549877T3
(es)
|
2008-09-07 |
2015-11-02 |
Glyconex Inc. |
Anticuerpo antiglucoesfingolípido de tipo I extendido, derivados del mismo y utilización
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
CA2737597C
(en)
|
2008-10-16 |
2017-03-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
EP2340040B1
(de)
|
2008-10-22 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Modulierung von axonen-degeneration
|
JP2012507299A
(ja)
|
2008-10-31 |
2012-03-29 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Light標的分子およびその使用
|
US20110293605A1
(en)
|
2008-11-12 |
2011-12-01 |
Hasige Sathish |
Antibody formulation
|
CA2742871C
(en)
|
2008-11-13 |
2018-10-23 |
Herb Lin |
Methods and compositions for regulating iron homeostasis by modulation of bmp-6
|
KR20110112301A
(ko)
*
|
2008-11-18 |
2011-10-12 |
메리맥 파마슈티컬즈, 인크. |
인간 혈청 알부민 링커 및 그 콘쥬게이트
|
HUE024872T2
(en)
|
2008-11-22 |
2016-02-29 |
Hoffmann La Roche |
Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
|
US8211434B2
(en)
|
2008-11-26 |
2012-07-03 |
Allergan, Inc. |
KLK-13 antibody inhibitor for treating dry eye
|
WO2010065568A2
(en)
|
2008-12-01 |
2010-06-10 |
Laboratory Corporation Of America Holdings |
METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
|
PL2376535T3
(pl)
|
2008-12-09 |
2017-09-29 |
F.Hoffmann-La Roche Ag |
Przeciwciała ANTY-PD-L1 i ich zastosowanie do nasilania działania limfocytów T
|
ES2749232T3
(es)
|
2008-12-16 |
2020-03-19 |
Emd Millipore Corp |
Reactor de tanque agitado y procedimiento
|
CN102256993A
(zh)
|
2008-12-16 |
2011-11-23 |
米利波尔公司 |
蛋白的纯化
|
AU2009335788A1
(en)
|
2008-12-17 |
2011-07-07 |
Genentech, Inc. |
Hepatitis C virus combination therapy
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
CN102460152B
(zh)
|
2009-01-15 |
2014-11-26 |
美国控股实验室公司 |
通过测量Her-3确定患者反应的方法
|
CN102307875A
(zh)
|
2009-02-09 |
2012-01-04 |
苏伯俭股份有限公司 |
吡咯并嘧啶基axl激酶抑制剂
|
CA2752510C
(en)
|
2009-02-17 |
2024-01-23 |
Neil Bander |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
EP2398829A2
(de)
|
2009-02-23 |
2011-12-28 |
Glenmark Pharmaceuticals S.A. |
Humanisierte antikörper, die an cd19 binden, und ihre verwendungen
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010106535A1
(en)
|
2009-03-15 |
2010-09-23 |
Technion Research And Development Foundation Ltd. |
Soluble hla complexes for use in disease diagnosis
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
CN102356092B
(zh)
|
2009-03-20 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
KR101822663B1
(ko)
|
2009-03-25 |
2018-01-29 |
제넨테크, 인크. |
항-fgfr3 항체 및 그의 사용 방법
|
BRPI1011535A2
(pt)
|
2009-04-01 |
2016-03-29 |
Genentech Inc |
tratamento de distúrbios resistentes à insulina.
|
JP6132548B2
(ja)
|
2009-04-01 |
2017-05-24 |
ジェネンテック, インコーポレイテッド |
抗FcRH5抗体および免疫接合体および使用方法
|
EP2417156B1
(de)
|
2009-04-07 |
2015-02-11 |
Roche Glycart AG |
Trivalente, bispezifische antikörper
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
US8753631B2
(en)
*
|
2009-05-01 |
2014-06-17 |
New York University |
Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
|
KR20120041175A
(ko)
|
2009-05-14 |
2012-04-30 |
더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 |
미량 존재하는 인간 혈장 단백질 바이오마커의 신규 패널을 이용한 간성 섬유증의 임상적 진단
|
AU2010249787A1
(en)
|
2009-05-20 |
2011-12-22 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2010136168A2
(en)
|
2009-05-25 |
2010-12-02 |
Merck Patent Gmbh |
Continuous administration of integrin ligands for treating cancer
|
WO2010136569A1
(en)
|
2009-05-29 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
CN102597005A
(zh)
|
2009-06-23 |
2012-07-18 |
阿雷克森制药公司 |
与补体蛋白质结合的双特异性抗体
|
CN102471381A
(zh)
|
2009-07-07 |
2012-05-23 |
霍夫曼-拉罗奇有限公司 |
自身免疫性脱髓鞘疾病的诊断和治疗
|
CA2768711A1
(en)
|
2009-07-20 |
2011-01-27 |
Genentech, Inc. |
Gene expression markers for crohn's disease
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
CN102498129B
(zh)
|
2009-07-31 |
2016-03-02 |
霍夫曼-拉罗奇有限公司 |
使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
|
US20130017188A1
(en)
|
2009-07-31 |
2013-01-17 |
The Brigham And Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
US8512983B2
(en)
|
2009-08-11 |
2013-08-20 |
Martin Gawlitzek |
Production of proteins in glutamine-free cell culture media
|
US20110038871A1
(en)
|
2009-08-11 |
2011-02-17 |
Veena Viswanth |
Ccr2 inhibitors for treating conditions of the eye
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
AR077848A1
(es)
|
2009-08-15 |
2011-09-28 |
Genentech Inc |
Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado
|
US20120157471A1
(en)
|
2009-09-01 |
2012-06-21 |
Pfizer Inc. |
Benzimidazole derivatives
|
KR101764449B1
(ko)
|
2009-09-01 |
2017-08-02 |
제넨테크, 인크. |
변형된 단백질 a 용리를 통한 증진된 단백질 정제
|
AU2010289400B2
(en)
|
2009-09-02 |
2014-10-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
WO2011050069A1
(en)
|
2009-10-20 |
2011-04-28 |
Prometheus Laboratories Inc. |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
MX2012004647A
(es)
|
2009-10-22 |
2012-06-19 |
Genentech Inc |
Anticuerpos antihepsina y metodos para su uso.
|
CN104043126A
(zh)
|
2009-10-22 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
轴突变性的调节
|
EP2490718B1
(de)
|
2009-10-22 |
2016-01-13 |
F.Hoffmann-La Roche Ag |
Verfahren und zusammensetzungen zur modulation der hepsin-aktivierung des makrophagen-stimulierenden proteins
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
US20120316071A1
(en)
|
2009-11-04 |
2012-12-13 |
Vaughn Smider |
Methods for affinity maturation-based antibody optimization
|
RU2585488C2
(ru)
|
2009-11-05 |
2016-05-27 |
Дженентек, Инк. |
Способы и композиция для секреции гетерологичных полипептидов
|
SG10201408598XA
(en)
|
2009-11-30 |
2015-02-27 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US8772459B2
(en)
|
2009-12-02 |
2014-07-08 |
Imaginab, Inc. |
J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
TW201636048A
(zh)
|
2009-12-21 |
2016-10-16 |
建南德克公司 |
抗體調配物
|
JP5852010B2
(ja)
|
2009-12-23 |
2016-02-03 |
ジェネンテック, インコーポレイテッド |
抗Bv8抗体およびその使用
|
JP5728718B2
(ja)
|
2009-12-28 |
2015-06-03 |
オンコセラピー・サイエンス株式会社 |
抗cdh3抗体およびその使用
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
AU2011215900A1
(en)
|
2010-02-10 |
2012-07-26 |
Immunogen, Inc. |
CD20 antibodies and uses thereof
|
ES2607806T3
(es)
|
2010-02-12 |
2017-04-04 |
Pfizer Inc |
Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック, インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
NZ601293A
(en)
|
2010-02-23 |
2014-10-31 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2539435A2
(de)
*
|
2010-02-23 |
2013-01-02 |
Corning Incorporated |
Modifizierte substrate für den schutz von peptidimmobilisierten oberflächen aus gammastrahlungsabbau
|
MX369170B
(es)
|
2010-02-23 |
2019-10-30 |
Genentech Inc |
Combinación concurrente de un anticuerpo anti-vegf con carboplatino y gemcitabina para usarse en el tratamiento de cáncer ovárico.
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2542893A2
(de)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
|
US9556248B2
(en)
|
2010-03-19 |
2017-01-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
|
EP2550295A1
(de)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Antikörper gegen lrp6
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
JP2013533732A
(ja)
|
2010-05-03 |
2013-08-29 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
US9403855B2
(en)
|
2010-05-10 |
2016-08-02 |
Academia Sinica |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
US8691918B2
(en)
|
2010-05-17 |
2014-04-08 |
Emd Millipore Corporation |
Stimulus responsive polymers for the purification of biomolecules
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
PL2575847T5
(pl)
|
2010-05-25 |
2022-07-18 |
F.Hoffmann-La Roche Ag |
Sposoby oczyszczania polipeptydów
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
CN102985437B
(zh)
|
2010-05-28 |
2016-05-25 |
弗·哈夫曼-拉罗切有限公司 |
通过下调ldh和pdhk表达降低乳酸水平和增加多肽生产
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
NZ602840A
(en)
|
2010-06-03 |
2014-11-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
KR101839163B1
(ko)
|
2010-06-08 |
2018-03-15 |
제넨테크, 인크. |
시스테인 조작된 항체 및 접합체
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
CA2802857C
(en)
|
2010-06-16 |
2018-09-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Antibodies to endoplasmin and their use
|
AR082017A1
(es)
|
2010-06-18 |
2012-11-07 |
Genentech Inc |
Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
WO2012006503A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
CN103153328A
(zh)
|
2010-07-16 |
2013-06-12 |
默克专利股份有限公司 |
肽在乳腺癌和/或骨转移灶的治疗中的用途
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
RU2013106216A
(ru)
|
2010-08-03 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Биомаркеры хронической лимфоцитарной лейкемии
|
EP2600898A1
(de)
|
2010-08-05 |
2013-06-12 |
F.Hoffmann-La Roche Ag |
Antivirales zytokinfusionsprotein mit mhc-antikörper
|
EP2603237A4
(de)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
Anti-hämagglutinin-antikörperzusammensetzungen und verfahren zu ihrer anwendung
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
UA113712C2
(xx)
|
2010-08-13 |
2017-02-27 |
|
Антитіло до fap і способи його застосування
|
JP5841149B2
(ja)
|
2010-08-13 |
2016-01-13 |
ロシュ グリクアート アーゲー |
抗テネイシンca2抗体及び使用の方法
|
RU2013110875A
(ru)
|
2010-08-24 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
|
AR082518A1
(es)
|
2010-08-25 |
2012-12-12 |
Hoffmann La Roche |
Anticuerpos contra il-18r1 y usos de los mismos
|
EP3556396B1
(de)
|
2010-08-31 |
2022-04-20 |
Theraclone Sciences, Inc. |
Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
|
WO2012031027A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
CA2810668A1
(en)
|
2010-09-08 |
2012-03-15 |
Halozyme, Inc. |
Methods for assessing and identifying or evolving conditionally active therapeutic proteins
|
CA2813738A1
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
JP5802756B2
(ja)
|
2010-10-20 |
2015-11-04 |
ファイザー・インク |
スムーズンド受容体モジュレーターとしてのピリジン−2−誘導体
|
EP3214442A1
(de)
|
2010-10-25 |
2017-09-06 |
F. Hoffmann-La Roche AG |
Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a
|
WO2012064836A1
(en)
|
2010-11-10 |
2012-05-18 |
Genentech, Inc. |
Methods and compositions for neural disease immunotherapy
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
WO2012075333A2
(en)
|
2010-12-02 |
2012-06-07 |
Prometheus Laboratories Inc. |
Her2delta16 peptides
|
CA3040095C
(en)
|
2010-12-16 |
2021-09-07 |
Genentech, Inc. |
Diagnosis and treatments relating to th2 inhibition
|
JP6253987B2
(ja)
|
2010-12-20 |
2017-12-27 |
ジェネンテック, インコーポレイテッド |
抗メソテリン抗体及びイムノコンジュゲート
|
BR112013015687A2
(pt)
|
2010-12-22 |
2016-10-11 |
Genentech Inc |
anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito
|
CN103384825B
(zh)
|
2010-12-23 |
2017-05-24 |
霍夫曼-拉罗奇有限公司 |
通过二价结合剂检测经翻译后修饰的多肽
|
EP2655414B1
(de)
|
2010-12-23 |
2018-08-29 |
Roche Diagniostics GmbH |
Bispezifisches bindungsmolekül
|
EP2659275B1
(de)
|
2010-12-23 |
2017-11-22 |
Roche Diagnostics GmbH |
Erkennung eines polypeptiddimers durch ein bivalentes bindemittel
|
JP2014503821A
(ja)
|
2010-12-23 |
2014-02-13 |
ネステク ソシエテ アノニム |
抗体ベースのアレイを用いる悪性がんの療法のための薬剤選択
|
EP2655413B1
(de)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
JP5878182B2
(ja)
|
2011-02-10 |
2016-03-08 |
ロシュ グリクアート アーゲー |
ミュータントインターロイキン−2ポリペプチド
|
RU2013139267A
(ru)
|
2011-02-10 |
2015-03-20 |
Рош Гликарт Аг |
Улучшенная иммунотерапия
|
SG192727A1
(en)
|
2011-02-14 |
2013-09-30 |
Theraclone Sciences Inc |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
BR112013023050A8
(pt)
|
2011-03-09 |
2018-09-25 |
G Pestell Richard |
antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal
|
CA2829968A1
(en)
|
2011-03-15 |
2012-09-20 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
PL3235508T3
(pl)
|
2011-03-16 |
2021-07-12 |
Sanofi |
Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
|
DK2691417T3
(en)
|
2011-03-29 |
2018-11-19 |
Roche Glycart Ag |
ANTIBODY FC VARIANTS
|
MY189494A
(en)
|
2011-03-31 |
2022-02-16 |
Genentech Inc |
Methods of administering beta7 integrin antagonists
|
EP2694551A1
(de)
|
2011-04-07 |
2014-02-12 |
Genentech, Inc. |
Anti-fgfr4-antikörper und verfahren zu ihrer verwendung
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
ES2724801T3
(es)
|
2011-04-19 |
2019-09-16 |
Pfizer |
Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
|
AU2012244816B2
(en)
|
2011-04-20 |
2015-12-10 |
Roche Glycart Ag |
Method and constructs for the pH dependent passage of the blood-brain-barrier
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
JP5987053B2
(ja)
|
2011-05-12 |
2016-09-06 |
ジェネンテック, インコーポレイテッド |
フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングlc−ms/ms法
|
US9085626B2
(en)
|
2011-05-16 |
2015-07-21 |
Genentech, Inc. |
FGFR1 agonists and methods of use
|
AR086924A1
(es)
|
2011-06-15 |
2014-01-29 |
Hoffmann La Roche |
Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
|
WO2013003680A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
TR201807040T4
(tr)
|
2011-07-11 |
2018-06-21 |
Glenmark Pharmaceuticals Sa |
Ox40 a bağlanan antikorlar ve bunların kullanımları.
|
EP3812387A1
(de)
|
2011-07-21 |
2021-04-28 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Heterocyclische proteinkinase-hemmer
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
CN103890008A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
在顽固性肿瘤中抑制血管发生
|
RS57744B1
(sr)
|
2011-08-23 |
2018-12-31 |
Roche Glycart Ag |
Bispecifični antigen vezujući molekuli
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
LT2748201T
(lt)
|
2011-08-23 |
2018-02-26 |
Roche Glycart Ag |
Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
|
CN103890006A
(zh)
|
2011-08-23 |
2014-06-25 |
罗切格利卡特公司 |
抗mcsp抗体
|
JP6159724B2
(ja)
|
2011-08-23 |
2017-07-05 |
ロシュ グリクアート アーゲー |
T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
KR101851425B1
(ko)
|
2011-09-02 |
2018-04-23 |
네스텍 소시에테아노님 |
치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
|
GB201212550D0
(en)
|
2012-07-13 |
2012-08-29 |
Novartis Ag |
B cell assay
|
CA2846083A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
SG11201400724SA
(en)
|
2011-09-19 |
2014-04-28 |
Genentech Inc |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
CN103814030A
(zh)
|
2011-09-22 |
2014-05-21 |
辉瑞大药厂 |
吡咯并嘧啶及嘌呤衍生物
|
AU2011378675B2
(en)
|
2011-10-04 |
2017-10-05 |
Epsilogen Ltd |
IgE anti -HMW-MAA antibody
|
CA2849011A1
(en)
|
2011-10-05 |
2013-04-11 |
Genentech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
RU2014119426A
(ru)
|
2011-10-15 |
2015-11-20 |
Дженентек, Инк. |
Способы применения антагонистов scd1
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
CN104039340B
(zh)
|
2011-10-28 |
2017-04-05 |
霍夫曼-拉罗奇有限公司 |
治疗黑素瘤的方法及治疗剂组合
|
CN107163101B
(zh)
|
2011-11-02 |
2021-08-17 |
弗·哈夫曼-拉罗切有限公司 |
超载和洗脱层析
|
AU2012335247A1
(en)
|
2011-11-08 |
2014-05-29 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-M-CSF antibodies
|
SG11201402485UA
(en)
|
2011-11-21 |
2014-06-27 |
Genentech Inc |
Purification of anti-c-met antibodies
|
AU2012340623A1
(en)
|
2011-11-23 |
2014-07-17 |
Igenica Biotherapeutics, Inc. |
Anti-CD98 antibodies and methods of use thereof
|
US20130143237A1
(en)
|
2011-11-29 |
2013-06-06 |
Genentech, Inc. |
Compositions and methods for prostate cancer analysis
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
KR102184059B1
(ko)
|
2011-12-22 |
2020-11-30 |
에프. 호프만-라 로슈 아게 |
발현 벡터 구성, 신규한 생산 세포 생성 방법 및 폴리펩티드의 재조합 생산을 위한 그의 용도
|
SG11201403443WA
(en)
|
2011-12-22 |
2014-07-30 |
Hoffmann La Roche |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
SG11201403437TA
(en)
|
2011-12-22 |
2014-07-30 |
Genentech Inc |
Ion exchange membrane chromatography
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
CN104066449B
(zh)
|
2012-01-18 |
2018-04-27 |
霍夫曼-拉罗奇有限公司 |
抗lrp5抗体及使用方法
|
US20130183294A1
(en)
|
2012-01-18 |
2013-07-18 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
CA2863066A1
(en)
|
2012-01-31 |
2013-08-08 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
CA2861124A1
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
CN104718220A
(zh)
|
2012-02-11 |
2015-06-17 |
霍夫曼-拉罗奇有限公司 |
R-spondin易位及其使用方法
|
JP6152120B2
(ja)
|
2012-02-15 |
2017-06-21 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Fc受容体に基づくアフィニティークロマトグラフィー
|
KR20140130455A
(ko)
|
2012-03-02 |
2014-11-10 |
로슈 글리카트 아게 |
Adcc-강화 항체를 사용한 암 치료용 예측 바이오마커
|
US20140170159A9
(en)
|
2012-03-08 |
2014-06-19 |
Ge Wei |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
CN104220457A
(zh)
|
2012-03-27 |
2014-12-17 |
霍夫曼-拉罗奇有限公司 |
涉及her3抑制剂的诊断和治疗
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
US20130336973A1
(en)
|
2012-05-10 |
2013-12-19 |
Zymeworks Inc. |
Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
WO2013173312A1
(en)
|
2012-05-14 |
2013-11-21 |
Pestell Richard G |
Using modulators of ccr5 for treating cancer
|
KR101843614B1
(ko)
|
2012-05-23 |
2018-03-29 |
제넨테크, 인크. |
치료제의 선택 방법
|
CN104520330A
(zh)
|
2012-06-08 |
2015-04-15 |
格兰马克药品股份有限公司 |
具有氨基酸取代的人源化抗TrkA抗体
|
KR20150023711A
(ko)
|
2012-06-15 |
2015-03-05 |
제넨테크, 인크. |
항-pcsk9 항체, 제제, 투여, 및 사용 방법
|
CN104411718B
(zh)
|
2012-06-27 |
2018-04-24 |
弗·哈夫曼-拉罗切有限公司 |
用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
|
MX354862B
(es)
|
2012-06-27 |
2018-03-23 |
Hoffmann La Roche |
Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
|
EP2867255B1
(de)
|
2012-06-27 |
2017-07-19 |
F. Hoffmann-La Roche AG |
Verfahren zur auswahl und herstellung massgeschneiderter, selektiver und multispezifischer therapiemoleküle mit mindestens zwei verschiedenen targeting-einheiten sowie verwendungen davon
|
BR112014030844A2
(pt)
|
2012-07-04 |
2019-10-15 |
Hoffmann La Roche |
anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
|
JP6148729B2
(ja)
|
2012-07-04 |
2017-06-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合している抗原−抗体結合体
|
CN104394886B
(zh)
|
2012-07-04 |
2017-05-24 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
KR20150030693A
(ko)
|
2012-07-05 |
2015-03-20 |
제넨테크, 인크. |
발현 및 분비 시스템
|
BR112015000441A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
|
EA201590173A1
(ru)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела к cd22
|
AR091700A1
(es)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd79b
|
PE20150614A1
(es)
|
2012-07-09 |
2015-05-25 |
Genentech Inc |
Inmunoconjugados que comprenden un anticuerpo anti-cd79b ligado a un derivado de nemorrubicina
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
PL3495387T3
(pl)
|
2012-07-13 |
2022-01-10 |
Roche Glycart Ag |
Dwuswoiste przeciwciała anty-VEGF/anty-ANG-2 i ich zastosowanie w leczeniu chorób naczyniowych oka
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
SG11201407580YA
(en)
|
2012-08-07 |
2014-12-30 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
WO2014023673A1
(en)
|
2012-08-08 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-10 fusion proteins and uses thereof
|
RU2015107891A
(ru)
|
2012-08-09 |
2016-09-27 |
Роше Гликарт Аг |
Антитела к asgpr и их применения
|
EP2885311B1
(de)
|
2012-08-18 |
2020-01-01 |
Academia Sinica |
Zelldurchlässige sonden zur identifikation und abbildung von sialidasen
|
US9547009B2
(en)
|
2012-08-21 |
2017-01-17 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
BR112015003938A2
(pt)
|
2012-09-14 |
2018-09-04 |
Hoffmann La Roche |
métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico
|
KR101850591B1
(ko)
|
2012-10-05 |
2018-04-19 |
제넨테크, 인크. |
염증성 장 질환의 진단 및 치료 방법
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
WO2014059028A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
JP6243918B2
(ja)
|
2012-10-16 |
2017-12-06 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Pkm2調節因子およびそれらの使用方法
|
EP2914621B1
(de)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Neuartige ntrk1-fusionsmoleküle und verwendungen davon
|
EA201500502A1
(ru)
|
2012-11-08 |
2015-10-30 |
Ф.Хоффманн-Ля Рош Аг |
Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3
|
AR093446A1
(es)
|
2012-11-13 |
2015-06-10 |
Genentech Inc |
Anticuerpos de antihemaglutinina y metodos de uso
|
JP2015537212A
(ja)
|
2012-11-15 |
2015-12-24 |
ジェネンテック, インコーポレイテッド |
イオン強度媒介のph勾配イオン交換クロマトグラフィー
|
RU2692773C2
(ru)
|
2012-11-30 |
2019-06-27 |
Ф.Хоффманн-Ля Рош Аг |
Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
CA2896894A1
(en)
|
2013-01-02 |
2014-07-10 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to tl1a and their uses
|
EP2945652B1
(de)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Verfahren zur behandlung cholangiokarzinom
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
CN104936985A
(zh)
|
2013-02-26 |
2015-09-23 |
罗切格利卡特公司 |
双特异性t细胞活化性抗原结合分子
|
KR20150123811A
(ko)
|
2013-02-26 |
2015-11-04 |
로슈 글리카트 아게 |
항-mcsp 항체
|
MX2015010350A
(es)
|
2013-02-26 |
2015-10-29 |
Roche Glycart Ag |
Moleculas de union a antigeno biespecificas que activan la celula t.
|
EA201891502A1
(ru)
|
2013-02-26 |
2018-12-28 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
KR20150123250A
(ko)
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
SG10201913932VA
(en)
|
2013-03-13 |
2020-03-30 |
Genentech Inc |
Antibody formulations
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
KR102237885B1
(ko)
|
2013-03-13 |
2021-04-07 |
제넨테크, 인크. |
감소된 산화를 갖는 제제
|
RU2707550C2
(ru)
|
2013-03-13 |
2019-11-27 |
Дженентек, Инк. |
Составы со сниженным окислением
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
SG11201507037XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Anti-b7-h4 antibodies and immunoconjugates
|
CA2903480A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
CA2905993C
(en)
|
2013-03-14 |
2022-12-06 |
Tolero Pharmaceuticals, Inc. |
Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
|
BR112015022529A2
(pt)
|
2013-03-15 |
2017-07-18 |
Genentech Inc |
meios de cultura de células e processos de produção de anticorpo
|
WO2014150877A2
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
TW201511770A
(zh)
|
2013-03-15 |
2015-04-01 |
Genentech Inc |
診斷及治療肝癌之組合物及方法
|
WO2014151006A2
(en)
|
2013-03-15 |
2014-09-25 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
KR20150131177A
(ko)
|
2013-03-15 |
2015-11-24 |
제넨테크, 인크. |
항-CRTh2 항체 및 그의 용도
|
CN110951670A
(zh)
|
2013-03-15 |
2020-04-03 |
豪夫迈·罗氏有限公司 |
具有抗氧化剂的细胞培养组合物和多肽生产方法
|
EP2968537A1
(de)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
|
SG10201708048XA
(en)
|
2013-03-18 |
2017-10-30 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
BR112015024856A2
(pt)
|
2013-03-27 |
2018-04-17 |
Genentech Inc |
métodos de determinação ou de monitoramento
|
EP2983710B1
(de)
|
2013-04-09 |
2019-07-31 |
Annexon, Inc. |
Behandlungsverfahren für neuromyelitis optica
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
CA2913108A1
(en)
|
2013-05-24 |
2014-11-27 |
Nestec S.A. |
Pathway specific assays for predicting irritable bowel syndrome diagnosis
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
EP3013347B1
(de)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glykankonjugate und verwendung davon
|
SG10201710758PA
(en)
|
2013-07-09 |
2018-02-27 |
Annexon Inc |
Anti-complement factor c1q antibodies and uses thereof
|
SI3019516T1
(sl)
|
2013-07-12 |
2019-02-28 |
F. Hoffmann-La Roche Ag |
Določitev optimalnih vhodnih parametrov za ionsko izmenjevalno kromatografijo
|
AU2014290044B2
(en)
*
|
2013-07-17 |
2020-10-29 |
Foundation Medicine, Inc. |
Methods of treating urothelial carcinomas
|
WO2015010100A2
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
KR20160042438A
(ko)
|
2013-08-12 |
2016-04-19 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
US20150093800A1
(en)
|
2013-09-05 |
2015-04-02 |
Genentech, Inc. |
Method for chromatography reuse
|
CN105682666B
(zh)
|
2013-09-06 |
2021-06-01 |
中央研究院 |
使用醣脂激活人类iNKT细胞
|
WO2015038984A2
(en)
|
2013-09-12 |
2015-03-19 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
CN105722992B
(zh)
|
2013-09-13 |
2021-04-20 |
豪夫迈·罗氏有限公司 |
用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法
|
MY193481A
(en)
|
2013-09-13 |
2022-10-17 |
Genentech Inc |
Method and compositions comprising purified recombinant polypeptides
|
CA2922889A1
(en)
|
2013-09-17 |
2015-03-26 |
Genentech, Inc. |
Methods of using anti-lgr5 antibodies
|
EP3049437A1
(de)
|
2013-09-27 |
2016-08-03 |
F. Hoffmann-La Roche AG |
Thermus-thermophilus-slyd-fkbp-domänenspezifische antikörper
|
TWI660738B
(zh)
|
2013-09-27 |
2019-06-01 |
建南德克公司 |
抗-pdl1抗體調配物
|
KR20160058960A
(ko)
|
2013-10-04 |
2016-05-25 |
압토스 바이오사이언시스 인코포레이티드 |
암을 치료하기 위한 조성물과 방법
|
EP3055328A1
(de)
|
2013-10-11 |
2016-08-17 |
F. Hoffmann-La Roche AG |
Nsp4-hemmer und verfahren zur verwendung
|
CN105612182B
(zh)
|
2013-10-11 |
2019-12-10 |
豪夫迈·罗氏有限公司 |
多特异性结构域交换共有可变轻链抗体
|
WO2015058132A2
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
RU2016119425A
(ru)
|
2013-10-23 |
2017-11-28 |
Дженентек, Инк. |
Способы диагностики и лечения эозинофильных заболеваний
|
CN105940113A
(zh)
|
2013-11-13 |
2016-09-14 |
酵活有限公司 |
靶向egfr和/或her2的单价抗原结合构建体及其用途
|
SG10202007189VA
(en)
|
2013-11-21 |
2020-09-29 |
Hoffmann La Roche |
ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CN105980409B
(zh)
|
2013-11-27 |
2023-07-18 |
酵活生物制药有限公司 |
靶向her2的双特异性抗原结合构建体
|
CN113861293A
(zh)
|
2013-12-09 |
2021-12-31 |
爱乐科斯公司 |
抗Siglec-8抗体及其使用方法
|
WO2015089344A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
PL3083689T3
(pl)
|
2013-12-17 |
2020-10-19 |
Genentech, Inc. |
Przeciwciała anty-CD3 i sposoby ich zastosowania
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
EP3680254A1
(de)
|
2013-12-17 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Verfahren zur behandlung von her2-positiven karzinomen mit pd-1 bindungsantagonisten und anti-her2-antikörpern
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
WO2015091656A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
JP6602304B2
(ja)
|
2014-01-03 |
2019-11-06 |
エフ.ホフマン−ラ ロシュ アーゲー |
共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
|
EP3089996B1
(de)
|
2014-01-03 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Bispezifische anti-hapten-/anti-blut-hirn-schranke-rezeptor-antikörper, komplexe davon und deren verwendung als blut-hirn-schranke-shuttles
|
MX2016008191A
(es)
|
2014-01-03 |
2017-11-16 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
CN111057151B
(zh)
|
2014-01-06 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
CA2936377A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for treating egfr expressing tumors
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP3094352B1
(de)
|
2014-01-16 |
2020-09-23 |
Academia Sinica |
Zusammensetzungen und verfahren zur behandlung und zum nachweis von krebs
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP3097122B9
(de)
|
2014-01-24 |
2020-11-11 |
NGM Biopharmaceuticals, Inc. |
Beta-klotho 2 bindende antikörper und verfahren zur verwendung davon
|
MX2016009515A
(es)
|
2014-01-24 |
2016-10-26 |
Genentech Inc |
Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados.
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
SG10201913637RA
(en)
|
2014-02-08 |
2020-03-30 |
Genentech Inc |
Methods of treating alzheimer's disease
|
ES2873248T3
(es)
|
2014-02-08 |
2021-11-03 |
Hoffmann La Roche |
Métodos para tratar la enfermedad de Alzheimer
|
US9518121B2
(en)
|
2014-02-12 |
2016-12-13 |
Genentech, Inc. |
Anti-Jagged1 antibodies and methods of use
|
SG11201606870XA
(en)
|
2014-02-21 |
2016-09-29 |
Genentech Inc |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
EP4014995A1
(de)
|
2014-02-28 |
2022-06-22 |
Allakos Inc. |
Verfahren und zusammensetzungen zur behandlung von siglec-8-assoziierten krankheiten
|
CN113583129A
(zh)
|
2014-03-14 |
2021-11-02 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
JP6644717B2
(ja)
|
2014-03-14 |
2020-02-12 |
ジェネンテック, インコーポレイテッド |
異種ポリペプチドを分泌させるための方法及び組成物
|
EP3119423B1
(de)
|
2014-03-15 |
2022-12-14 |
Novartis AG |
Behandelung von krebs mit einem chimären antigenrezeptor
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
MA39776A
(fr)
|
2014-03-24 |
2017-02-01 |
Hoffmann La Roche |
Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
|
EP3122377A4
(de)
|
2014-03-27 |
2018-03-14 |
F.Hoffmann-La Roche Ag |
Verfahren zur diagnose und behandlung von entzündlicher darmerkrankung
|
TWI687428B
(zh)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
反應性標記化合物及其用途
|
JP6637439B2
(ja)
|
2014-03-31 |
2020-01-29 |
ジェネンテック, インコーポレイテッド |
抗ox40抗体及び使用方法
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
MA52909A
(fr)
|
2014-04-18 |
2021-04-21 |
Acceleron Pharma Inc |
Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
NZ725496A
(en)
|
2014-04-30 |
2019-11-29 |
Pfizer |
Cycloalkyl-linked diheterocycle derivatives
|
WO2015168468A1
(en)
|
2014-05-01 |
2015-11-05 |
Genentech, Inc. |
Anti-factor d antibody variants and uses thereof
|
AU2015255883A1
(en)
|
2014-05-08 |
2016-10-27 |
Novodiax, Inc. |
Direct immunohistochemistry assay
|
CN106414499A
(zh)
|
2014-05-22 |
2017-02-15 |
基因泰克公司 |
抗gpc3抗体和免疫偶联物
|
WO2015179835A2
(en)
|
2014-05-23 |
2015-11-26 |
Genentech, Inc. |
Mit biomarkers and methods using the same
|
AU2015267047A1
(en)
|
2014-05-27 |
2017-01-05 |
Academia Sinica |
Anti-CD20 glycoantibodies and uses thereof
|
EP3904388A1
(de)
|
2014-05-27 |
2021-11-03 |
Academia Sinica |
Fucosidase aus bacteroiden und verfahren damit
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
BR112016028838A2
(pt)
|
2014-06-11 |
2017-10-24 |
Genentech Inc |
anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
|
EP3154589A1
(de)
|
2014-06-13 |
2017-04-19 |
Genentech, Inc. |
Verfahren zur behandlung und prävention der antikrebsmittelresistenz
|
EP3154566B1
(de)
|
2014-06-13 |
2022-08-03 |
Acceleron Pharma Inc. |
Actrii antagonist zur behandlung oder prävention eines hautulzers in einem patienten mit anämie
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
MX2016015280A
(es)
|
2014-06-26 |
2017-03-03 |
Hoffmann La Roche |
Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
CN113789339A
(zh)
|
2014-07-03 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
多肽表达***
|
ES2903029T3
(es)
|
2014-07-03 |
2022-03-30 |
Univ Yale |
La inhibición de DICKKOPF2 (DKK2) suprime la formación de tumores
|
CA2954446A1
(en)
|
2014-07-09 |
2016-01-14 |
Shanghai Birdie Biotech, Inc. |
Anti-pd-l1 combinations for treating tumors
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于***的抗-pd-l1结合物
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CA2954868C
(en)
|
2014-07-11 |
2023-08-29 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
EP3166627A1
(de)
|
2014-07-11 |
2017-05-17 |
Genentech, Inc. |
Notch-signalweghemmung
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3172237A2
(de)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Behandlung von krebs mithilfe von humanisiertem chimärem anti-bcma-antigenrezeptor
|
ES2805475T3
(es)
|
2014-07-21 |
2021-02-12 |
Novartis Ag |
Tratamiento del cáncer utilizando un receptor antigénico quimérico de CD33
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
KR102317315B1
(ko)
|
2014-08-04 |
2021-10-27 |
에프. 호프만-라 로슈 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
SG10201913611QA
(en)
|
2014-08-08 |
2020-03-30 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
TW202140557A
(zh)
|
2014-08-19 |
2021-11-01 |
瑞士商諾華公司 |
使用cd123嵌合抗原受體治療癌症
|
TR201907471T4
(tr)
|
2014-08-28 |
2019-06-21 |
Halozyme Inc |
Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
|
US20170260261A1
(en)
|
2014-08-28 |
2017-09-14 |
Bioatla, Llc |
Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
|
KR102422375B1
(ko)
|
2014-09-08 |
2022-07-18 |
아카데미아 시니카 |
당지질을 사용한 인간 iNKT 세포 활성화
|
WO2016040868A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
KR20170052600A
(ko)
|
2014-09-12 |
2017-05-12 |
제넨테크, 인크. |
시스테인 가공된 항체 및 콘주게이트
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗-b7-h4抗體及免疫結合物
|
MY186334A
(en)
|
2014-09-12 |
2021-07-12 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
ES2949173T3
(es)
|
2014-09-15 |
2023-09-26 |
Hoffmann La Roche |
Formulaciones de anticuerpo
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CA2957148A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
PL3262071T3
(pl)
|
2014-09-23 |
2020-08-10 |
F. Hoffmann-La Roche Ag |
Sposób stosowania immunokoniugatów anty-CD79b
|
CN107001478B
(zh)
|
2014-10-14 |
2022-01-11 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
WO2016061389A2
(en)
|
2014-10-16 |
2016-04-21 |
Genentech, Inc. |
Anti-alpha-synuclein antibodies and methods of use
|
WO2016073380A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
JP6702991B2
(ja)
|
2014-11-03 |
2020-06-03 |
ジェネンテック, インコーポレイテッド |
T細胞免疫サブセットを検出するためのアッセイ及びその使用の方法
|
BR112017009297B1
(pt)
|
2014-11-05 |
2024-02-15 |
Annexon, Inc |
Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
|
AU2015342961B2
(en)
|
2014-11-05 |
2021-08-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
ES2819256T3
(es)
|
2014-11-05 |
2021-04-15 |
Genentech Inc |
Métodos para producir proteínas bicatenarias en bacterias
|
WO2016073789A2
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
RU2017119428A
(ru)
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
JP2018500882A
(ja)
|
2014-11-10 |
2018-01-18 |
ジェネンテック, インコーポレイテッド |
腎症の動物モデルおよびそれを治療するための薬剤
|
JP6929771B2
(ja)
|
2014-11-10 |
2021-09-01 |
ジェネンテック, インコーポレイテッド |
抗インターロイキン−33抗体及びその使用
|
RS61870B1
(sr)
|
2014-11-14 |
2021-06-30 |
Hoffmann La Roche |
Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
SG11201703729RA
(en)
|
2014-11-19 |
2017-06-29 |
Nestec Sa |
Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
|
EP3845565A3
(de)
|
2014-11-19 |
2021-09-08 |
Genentech, Inc. |
Antikörper gegen bace1 und verwendung davon zur immuntherapie bei neuronalen erkrankungen
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
ES2835823T3
(es)
|
2014-11-20 |
2021-06-23 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
|
MX2017006626A
(es)
|
2014-11-20 |
2017-08-21 |
Hoffmann La Roche |
Cadenas ligeras comunes y metodos de uso.
|
US20170269092A1
(en)
|
2014-12-02 |
2017-09-21 |
Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
CR20170230A
(es)
|
2014-12-05 |
2017-11-07 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
SG11201703750XA
(en)
|
2014-12-10 |
2017-06-29 |
Genentech Inc |
Blood brain barrier receptor antibodies and methods of use
|
WO2016094834A2
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
A method for treating a complement mediated disorder caused by an infectious agent in a patient
|
WO2016097918A1
(en)
|
2014-12-18 |
2016-06-23 |
Pfizer Inc. |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
EP3034130B1
(de)
|
2014-12-19 |
2019-12-04 |
Althia Health, S.L. |
Monoklonaler Antikörper zur Diagnose, Behandlung und/oder Prävention von Hirntumoren und Hirnverletzungen
|
CN107207607B
(zh)
|
2014-12-19 |
2021-05-04 |
中外制药株式会社 |
抗-c5抗体及使用方法
|
CN107530423B
(zh)
|
2015-01-14 |
2022-04-05 |
布里格姆及妇女医院股份有限公司 |
用抗lap单克隆抗体治疗癌症
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
JP2018511557A
(ja)
|
2015-01-22 |
2018-04-26 |
中外製薬株式会社 |
2種以上の抗c5抗体の組み合わせおよび使用方法
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
AU2016209056B2
(en)
|
2015-01-24 |
2021-01-28 |
Academia Sinica |
Cancer markers and methods of use thereof
|
EP3250927B1
(de)
|
2015-01-28 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Genexpressionsmarker und behandlung von multipler sklerose
|
KR102620346B1
(ko)
|
2015-01-30 |
2024-01-02 |
아카데미아 시니카 |
증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
|
EP3253784B1
(de)
|
2015-02-04 |
2020-05-06 |
Genentech, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
EP3816179A3
(de)
|
2015-02-05 |
2021-08-04 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-region-variante, mit einer modifizierten fcrn-bindungsdomäne
|
CN107810192A
(zh)
|
2015-02-23 |
2018-03-16 |
海鸥治疗简易股份公司 |
非天然的脑信号蛋白3及其医药用途
|
MX2017010336A
(es)
|
2015-02-26 |
2017-12-20 |
Genentech Inc |
Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
|
KR20170122216A
(ko)
|
2015-03-06 |
2017-11-03 |
제넨테크, 인크. |
초순수화 dsba 및 dsbc와 이를 제조하고 사용하는 방법
|
AU2016233398A1
(en)
|
2015-03-16 |
2017-09-07 |
F. Hoffmann-La Roche Ag |
Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases
|
US10780179B2
(en)
|
2015-03-18 |
2020-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
EP3828199A1
(de)
|
2015-04-06 |
2021-06-02 |
Acceleron Pharma Inc. |
Alk7: actriib-heteromultimere und verwendungen davon
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
EA201792221A1
(ru)
|
2015-04-07 |
2018-08-31 |
ЭЛЕКТОР ЭлЭлСи |
Антитела против сортилина и способы их применения
|
CA2981183A1
(en)
|
2015-04-07 |
2016-10-13 |
Greg Lazar |
Antigen binding complex having agonistic activity and methods of use
|
LT3280729T
(lt)
|
2015-04-08 |
2022-08-10 |
Novartis Ag |
Terapijos cd20, terapijos cd22 ir kombinuotos terapijos su cd19 chimerinį antigeno receptorių (car) ekspresuojančia ląstele
|
EP3611506B1
(de)
|
2015-04-20 |
2021-11-17 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Vorhersage der therapeutischen reaktion auf alvocidib durch mitochondriales profilieren
|
EP3286565A1
(de)
|
2015-04-21 |
2018-02-28 |
Genentech, Inc. |
Zusammensetzungen und verfahren für prostatakrebsanalyse
|
GB201506870D0
(en)
*
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
EP3286211A1
(de)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
|
ES2881694T3
(es)
|
2015-04-24 |
2021-11-30 |
Hoffmann La Roche |
Procedimientos de identificación de bacterias que comprenden polipéptidos de unión
|
WO2016178876A2
(en)
|
2015-05-01 |
2016-11-10 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
JP2018520642A
(ja)
|
2015-05-01 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
マスク抗cd3抗体及びその使用方法
|
JP6963508B2
(ja)
|
2015-05-11 |
2021-11-10 |
ジェネンテック, インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
RS61152B1
(sr)
|
2015-05-12 |
2020-12-31 |
Hoffmann La Roche |
Terapeutski i dijagnostički postupci za lečenje raka
|
CA2985804A1
(en)
|
2015-05-18 |
2016-11-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs having increased bioavailability
|
ES2823033T3
(es)
|
2015-05-28 |
2021-05-05 |
Genentech Inc |
Ensayo basado en células para detectar homodímeros anti-CD3
|
IL255372B
(en)
|
2015-05-29 |
2022-07-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
EP3303619B1
(de)
|
2015-05-29 |
2020-06-10 |
H. Hoffnabb-La Roche Ag |
Pd-l1-promotormethylierung bei krebs
|
JP2018520658A
(ja)
|
2015-05-29 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
|
CN115554399A
(zh)
|
2015-05-31 |
2023-01-03 |
源生公司 |
用于免疫疗法的组合组合物
|
CN107810012A
(zh)
|
2015-06-02 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗il‑34抗体治疗神经疾病的组合物和方法
|
EP3303386A1
(de)
|
2015-06-05 |
2018-04-11 |
Genentech, Inc. |
Anti-tau-antikörper und verfahren zur verwendung
|
EP3303399A1
(de)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Verfahren zur krebsbehandlung mit anti-ox40-antikörpern
|
CA2988420A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
AU2016276981B2
(en)
|
2015-06-12 |
2022-10-06 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
AR104987A1
(es)
|
2015-06-15 |
2017-08-30 |
Genentech Inc |
Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
FI3310814T3
(fi)
|
2015-06-16 |
2023-09-21 |
Hoffmann La Roche |
HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ
|
CN107849145B
(zh)
|
2015-06-16 |
2021-10-26 |
基因泰克公司 |
抗cd3抗体及其使用方法
|
WO2016205567A1
(en)
|
2015-06-17 |
2016-12-22 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
JP2018524312A
(ja)
|
2015-06-17 |
2018-08-30 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び使用方法
|
CN116327953A
(zh)
|
2015-06-17 |
2023-06-27 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
PL3313877T3
(pl)
|
2015-06-24 |
2020-11-02 |
F. Hoffmann-La Roche Ag |
Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
|
ES2898065T3
(es)
|
2015-06-29 |
2022-03-03 |
Ventana Med Syst Inc |
Materiales y procedimientos para realizar ensayos histoquímicos para proepirregulina y anfirregulina humanas
|
CN108473573A
(zh)
|
2015-06-29 |
2018-08-31 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于器官移植中
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
EP3878465A1
(de)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen tim-3
|
US10568887B2
(en)
|
2015-08-03 |
2020-02-25 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
CN116327952A
(zh)
|
2015-08-04 |
2023-06-27 |
阿塞勒隆制药公司 |
用于治疗骨髓增生性病症的方法
|
MX2018001566A
(es)
|
2015-08-07 |
2019-04-25 |
Imaginab Inc |
Construcciones de union a antigeno para moleculas diana.
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
CA2996059A1
(en)
|
2015-08-28 |
2017-03-09 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
EP3341415B1
(de)
|
2015-08-28 |
2021-03-24 |
H. Hoffnabb-La Roche Ag |
Anti-hypusin-antikörper und verwendungen davon
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ,インコーポレイテッド |
グリカンアレイおよび使用の方法
|
JP2018528218A
(ja)
|
2015-09-11 |
2018-09-27 |
アンドリアン、ブルース |
組換えグリコシル化エクリズマブおよびエクリズマブ変異体
|
EP3350202A1
(de)
|
2015-09-18 |
2018-07-25 |
Chugai Seiyaku Kabushiki Kaisha |
Il-8-bindende antikörper und verwendungen davon
|
AU2016328357B2
(en)
|
2015-09-22 |
2023-03-02 |
Ventana Medical Systems, Inc. |
Anti-OX40 antibodies and diagnostic uses thereof
|
CN108137681A
(zh)
|
2015-09-23 |
2018-06-08 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
KR20180054824A
(ko)
|
2015-09-29 |
2018-05-24 |
셀진 코포레이션 |
Pd-1 결합 단백질 및 이의 사용 방법
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
CN108137699B
(zh)
|
2015-10-02 |
2022-05-27 |
豪夫迈·罗氏有限公司 |
对pd1和tim3特异性的双特异性抗体
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
AR106365A1
(es)
|
2015-10-02 |
2018-01-10 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
AU2016329120B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for a costimulatory TNF receptor
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
US20170096495A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MA43018B1
(fr)
|
2015-10-02 |
2021-11-30 |
Hoffmann La Roche |
Anticorps anti-pd1 et procédés d'utilisation
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
IL293708A
(en)
|
2015-10-06 |
2022-08-01 |
Genentech Inc |
A method for treating multiple sclerosis
|
KR20180068999A
(ko)
|
2015-10-06 |
2018-06-22 |
알렉터 엘엘씨 |
항-trem2 항체 및 그의 사용방법
|
CR20180171A
(es)
|
2015-10-07 |
2018-05-03 |
Hoffmann La Roche |
Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
|
WO2017062649A1
(en)
|
2015-10-07 |
2017-04-13 |
Alexion Pharmaceuticals, Inc. |
A method for treating age-related macular degeneration in a patient
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
CA3002903A1
(en)
|
2015-10-23 |
2017-04-27 |
Fred Hutchinson Cancer Research Center |
Methods to create chemically-induced dimerizing protein systems for regulation of cellular events
|
JP6921067B2
(ja)
|
2015-10-28 |
2021-08-18 |
イエール ユニバーシティ |
ヒト化抗Dkk2抗体およびその使用方法
|
KR20180069065A
(ko)
|
2015-10-29 |
2018-06-22 |
에프. 호프만-라 로슈 아게 |
항-변이체 fc-부위 항체 및 사용 방법
|
WO2017075432A2
(en)
|
2015-10-29 |
2017-05-04 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
EP3184547A1
(de)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg-antikörper und verfahren zur verwendung
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
JP6750010B2
(ja)
|
2015-10-30 |
2020-09-02 |
ジェネンテック, インコーポレイテッド |
抗HtrA1抗体及びその使用方法
|
US10654932B2
(en)
|
2015-10-30 |
2020-05-19 |
Genentech, Inc. |
Anti-factor D antibody variant conjugates and uses thereof
|
JP6998869B2
(ja)
|
2015-11-08 |
2022-02-04 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体のスクリーニング方法
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
AU2016359695A1
(en)
|
2015-11-23 |
2018-06-14 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
US20180371551A1
(en)
|
2015-12-03 |
2018-12-27 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
EP3178848A1
(de)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
|
CN108290954B
(zh)
|
2015-12-09 |
2022-07-26 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
DK3390441T3
(da)
|
2015-12-15 |
2021-10-11 |
Gilead Sciences Inc |
Antistoffer til neutralisering af human immundefekt virus
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
EP3389712B1
(de)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antikörpermoleküle gegen pd-1 und verwendungen davon
|
MY186948A
(en)
|
2015-12-18 |
2021-08-26 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
MX2018008063A
(es)
|
2015-12-30 |
2018-11-29 |
Genentech Inc |
Uso de derivados de triptofano para formulaciones de proteina.
|
WO2017117311A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
US20200270365A1
(en)
|
2016-01-05 |
2020-08-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
CN114113625A
(zh)
|
2016-01-20 |
2022-03-01 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
ES2847155T3
(es)
|
2016-01-21 |
2021-08-02 |
Novartis Ag |
Moléculas multiespecíficas que fijan como objetivo CLL-1
|
JP7438662B2
(ja)
|
2016-01-25 |
2024-02-27 |
ジェネンテック, インコーポレイテッド |
T細胞依存性二重特異的抗体をアッセイするための方法
|
EP3411396A1
(de)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Smoothened-mutant und verfahren zur verwendung davon
|
US10982136B2
(en)
|
2016-02-26 |
2021-04-20 |
The Regents Of The University Of California |
Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
|
CA3015528A1
(en)
|
2016-02-29 |
2017-09-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP7023853B2
(ja)
|
2016-03-04 |
2022-02-22 |
アレクトル エルエルシー |
抗trem1抗体及びその使用方法
|
CN109153714A
(zh)
|
2016-03-04 |
2019-01-04 |
诺华股份有限公司 |
表达多重嵌合抗原受体(car)分子的细胞及其用途
|
EP3216458A1
(de)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
JP6430025B2
(ja)
|
2016-03-15 |
2018-11-28 |
中外製薬株式会社 |
Pd−1系結合アンタゴニストおよび抗gpc3抗体を使用して癌を治療する方法
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
SI3433280T1
(sl)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
S proteazo aktivirane bispecifične molekule celic T
|
SG11201808085WA
(en)
|
2016-03-22 |
2018-10-30 |
Hoffmann La Roche |
Protease-activated t cell bispecific molecules
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
WO2017165734A1
(en)
|
2016-03-25 |
2017-09-28 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
BR112018070097A2
(pt)
|
2016-03-29 |
2019-02-12 |
Obi Pharma, Inc. |
anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3231813A1
(de)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
|
EP3865511A1
(de)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3-antikörper und verfahren zur verwendung
|
KR20180134385A
(ko)
|
2016-04-15 |
2018-12-18 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
EP3443350B1
(de)
|
2016-04-15 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Verfahren zur überwachung und behandlung von krebs
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
EP3443012A4
(de)
|
2016-04-15 |
2019-09-11 |
Bioatla, LLC |
Anti-axl-antikörper, antikörperfragmente und deren immunkonjugate und verwendungen davon
|
SG11201809024UA
(en)
|
2016-04-22 |
2018-11-29 |
Obi Pharma Inc |
Cancer immunotherapy by immune activation or immune modulation via globo series antigens
|
JP6675017B2
(ja)
|
2016-05-02 |
2020-04-01 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
コントースボディ−単鎖標的結合物質
|
EP3454863A1
(de)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationstherapien zur behandlung von krebs
|
EP3243836A1
(de)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie
|
CN109071652B
(zh)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
KR20230044567A
(ko)
|
2016-05-13 |
2023-04-04 |
바이오아트라, 인코퍼레이티드 |
항 ror2 항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
|
EP3243832A1
(de)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
|
MX2018014047A
(es)
|
2016-05-17 |
2019-06-20 |
Genentech Inc |
Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
|
EP3458101B1
(de)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac-antikörper-konjugate und verfahren zur verwendung
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
US10851159B2
(en)
|
2016-06-02 |
2020-12-01 |
Bloom Diagnostics Ag |
Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
|
EP3252078A1
(de)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
|
CN109476648B
(zh)
|
2016-06-06 |
2022-09-13 |
豪夫迈·罗氏有限公司 |
司维司群抗体-药物缀合物和使用方法
|
MX2018015173A
(es)
|
2016-06-17 |
2019-07-04 |
Genentech Inc |
Purificacion de anticuerpos multiespecificos.
|
CN109563160B
(zh)
|
2016-06-24 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
WO2018011691A1
(en)
|
2016-07-12 |
2018-01-18 |
Nestec S.A. |
Competitive immunoassay methods
|
AU2017297603A1
(en)
|
2016-07-14 |
2019-02-14 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
CA3030837A1
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
PT3496739T
(pt)
|
2016-07-15 |
2021-06-21 |
Acceleron Pharma Inc |
Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
WO2018022933A1
(en)
|
2016-07-27 |
2018-02-01 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
EP3490582A4
(de)
|
2016-07-27 |
2020-04-01 |
Acceleron Pharma Inc. |
Verfahren und zusammensetzungen zur behandlung von myelofibrose
|
WO2018023025A1
(en)
|
2016-07-28 |
2018-02-01 |
Novartis Ag |
Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
|
EP3491026A4
(de)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
|
JP7050677B2
(ja)
|
2016-07-29 |
2022-04-08 |
中外製薬株式会社 |
増強されたfviii補因子機能代替活性を有する二重特異性抗体
|
CN110267677A
(zh)
|
2016-08-01 |
2019-09-20 |
诺华股份有限公司 |
使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
|
TW202300168A
(zh)
|
2016-08-05 |
2023-01-01 |
日商中外製藥股份有限公司 |
Il-8相關疾病之治療用或預防用組成物
|
EP3494139B1
(de)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
EP3496763A1
(de)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepin-prodrugs und antikörperkonjugate davon
|
SG11201901228QA
(en)
|
2016-08-15 |
2019-03-28 |
Genentech Inc |
Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
|
JP7213549B2
(ja)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
抗体、結合性断片、および使用の方法
|
WO2018044812A2
(en)
|
2016-08-29 |
2018-03-08 |
Fred Hutchinson Cancer Research Center |
Chelating platform for delivery of radionuclides
|
EP3508576A4
(de)
|
2016-08-31 |
2020-04-22 |
Onco Therapy Science, Inc. |
Monoklonaler antikörper gegen melk und verwendung davon
|
CA3035966A1
(en)
|
2016-09-06 |
2018-03-15 |
The Regents Of The University Of California |
Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
|
EP3510046A4
(de)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
Antikörper gegen oxidationsspezifische epitope
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
JP6976315B2
(ja)
|
2016-09-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
補体因子に基づくアフィニティークロマトグラフィー
|
JP2019531284A
(ja)
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して免疫障害を治療する方法
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
KR102557643B1
(ko)
|
2016-09-23 |
2023-07-20 |
제넨테크, 인크. |
아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
|
JP7022123B2
(ja)
|
2016-09-30 |
2022-02-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd3に対する二重特異性抗体
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
JP2019529509A
(ja)
|
2016-10-05 |
2019-10-17 |
アクセレロン ファーマ インコーポレーテッド |
腎臓疾患を治療するための組成物および方法
|
EP3523451A1
(de)
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutische und diagnostische verfahren für krebs
|
TWI762516B
(zh)
|
2016-10-06 |
2022-05-01 |
日商腫瘤療法 科學股份有限公司 |
針對fzd10之單株抗體及其用途
|
US10525083B2
(en)
|
2016-10-07 |
2020-01-07 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
EP3529618B1
(de)
|
2016-10-19 |
2020-12-02 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur quantifizierung von ungebundenem c5 in einer probe
|
JP7173965B2
(ja)
|
2016-10-19 |
2022-11-16 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
試料中の非結合C5aの定量化方法
|
US11078298B2
(en)
|
2016-10-28 |
2021-08-03 |
Banyan Biomarkers, Inc. |
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
|
WO2018081648A2
(en)
|
2016-10-29 |
2018-05-03 |
Genentech, Inc. |
Anti-mic antibidies and methods of use
|
KR20190074300A
(ko)
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
EP3551220A1
(de)
|
2016-12-07 |
2019-10-16 |
Genentech, Inc. |
Anti-tau-antikörper und verfahren zur verwendung
|
MX2019006330A
(es)
|
2016-12-07 |
2019-09-26 |
Genentech Inc |
Anticuerpos anti-tau y metodos de uso.
|
CN110114674B
(zh)
|
2016-12-13 |
2023-05-09 |
豪夫迈·罗氏有限公司 |
确定肿瘤样品中存在靶抗原的方法
|
IL267284B2
(en)
|
2016-12-19 |
2023-03-01 |
Hoffmann La Roche |
Combination therapy with a targeted 4-bb1 agonist (cd137)
|
CA3047557A1
(en)
|
2016-12-19 |
2018-06-28 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
KR20190093588A
(ko)
|
2016-12-20 |
2019-08-09 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
EP3565843A1
(de)
|
2017-01-03 |
2019-11-13 |
H. Hoffnabb-La Roche Ag |
Bispezifische antigenbindende moleküle mit anti-4-1bb-klon 20h4.9
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
WO2018127791A2
(en)
|
2017-01-06 |
2018-07-12 |
Biosion, Inc. |
Erbb2 antibodies and uses therefore
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
MX2019009485A
(es)
|
2017-02-10 |
2019-11-05 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos.
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
EP3589754B1
(de)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnose- und therapieverfahren für krebs
|
CN110382529B
(zh)
|
2017-03-02 |
2024-03-08 |
诺华股份有限公司 |
工程化的异源二聚体蛋白质
|
WO2018175752A1
(en)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Optimized antibody compositions for treatment of ocular disorders
|
TWI808963B
(zh)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
使用人類化抗cxcr5抗體治療狼瘡
|
WO2018175788A1
(en)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
BR112019020168A2
(pt)
|
2017-03-27 |
2020-06-02 |
F. Hoffmann-La Roche Ag |
Receptores de ligação ao antígeno, células t transduzidas, polinucleotídeo isolado, vetor, kits, métodos para tratar uma doença e para induzir a lise de uma célula alvo e uso do receptor de ligação ao antígeno
|
CR20190431A
(es)
|
2017-03-27 |
2019-11-01 |
Hoffmann La Roche |
Formatos mejorados de receptor de unión a antígeno
|
SG10201911225WA
(en)
|
2017-03-28 |
2020-01-30 |
Genentech Inc |
Methods of treating neurodegenerative diseases
|
CN110573528B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
WO2018178076A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
DK3606946T3
(da)
|
2017-04-03 |
2022-10-24 |
Hoffmann La Roche |
Immunkonjugater af et anti-PD-1-antistof med et muteret IL-2 eller med IL-15
|
EP3606947B1
(de)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunokonjugat von il-2 mit einem bispezifischen antikörper gerichtet gegen pd-1 und tim-3
|
WO2018184966A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Antibodies binding to steap-1
|
JP6997209B2
(ja)
|
2017-04-04 |
2022-02-04 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd40およびfapに特異的に結合することができる新規な二重特異性抗原結合分子
|
TWI747215B
(zh)
|
2017-04-05 |
2021-11-21 |
瑞士商赫孚孟拉羅股份公司 |
特異性結合至pd1至lag3的雙特異性抗體
|
SI3606954T1
(sl)
|
2017-04-05 |
2022-10-28 |
F. Hoffmann - La Roche Ag |
Protitelesa proti LAG3
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
MX2019012419A
(es)
|
2017-04-21 |
2019-12-05 |
Genentech Inc |
Uso de antagonistas de klk5 para el tratamiento de una enfermedad.
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
CA3062415A1
(en)
|
2017-05-05 |
2018-11-08 |
Christopher Robert Bebbington |
Methods and compositions for treating allergic ocular diseases
|
EP3625251A1
(de)
|
2017-05-15 |
2020-03-25 |
University Of Rochester |
Breit neutralisierende monoklonale anti-influenza-antikörper und verwendungen davon
|
EP3625258A1
(de)
|
2017-05-16 |
2020-03-25 |
Alector LLC |
Anti-siglec-5-antikörper und verfahren zur verwendung davon
|
CN110753703B
(zh)
|
2017-05-23 |
2024-04-09 |
德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) |
新的cd73抗体、其制备和用途
|
EP3409322A1
(de)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Behandlungsverfahren
|
MX2019014274A
(es)
|
2017-06-02 |
2020-01-23 |
Hoffmann La Roche |
Metodo de tratamiento.
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
AU2018301393A1
(en)
|
2017-07-11 |
2020-02-06 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
US11674962B2
(en)
|
2017-07-21 |
2023-06-13 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
AU2018308364C1
(en)
|
2017-07-26 |
2023-02-16 |
Forty Seven, Inc. |
Anti-SIRP-alpha antibodies and related methods
|
EP3658183A1
(de)
|
2017-07-28 |
2020-06-03 |
H. Hoffnabb-La Roche Ag |
Bispezifische antikörperformulierung
|
EP3601358B1
(de)
|
2017-08-03 |
2023-05-17 |
Alector LLC |
Anti-trem2 antikörper und deren verwendung
|
CR20190486A
(es)
|
2017-08-03 |
2020-02-10 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
AU2018316343A1
(en)
|
2017-08-11 |
2020-02-13 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン
|
TWI667254B
(zh)
|
2017-09-29 |
2019-08-01 |
日商中外製藥股份有限公司 |
具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
BR112020007154A2
(pt)
|
2017-10-20 |
2020-09-29 |
F. Hoffmann-La Roche Ag |
método para produzir um polipeptídeo e polipeptídeos heterodimérico
|
EP3704145A1
(de)
|
2017-10-30 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Verfahren zur in-vivo-erzeugung multispezifischer antikörper aus monospezifischen antikörpern
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
AU2018358904A1
(en)
|
2017-11-01 |
2020-04-16 |
F. Hoffmann-La Roche Ag |
TriFab-contorsbody
|
WO2019086499A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Novel tnf family ligand trimer-containing antigen binding molecules
|
TWI829658B
(zh)
|
2017-11-01 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性2+1康特斯體(Contorsbody)
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
KR20200084006A
(ko)
|
2017-11-01 |
2020-07-09 |
에프. 호프만-라 로슈 아게 |
표적화된 ox40 작용제를 사용하는 병용 요법
|
KR20200075860A
(ko)
|
2017-11-06 |
2020-06-26 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
TW201922291A
(zh)
|
2017-11-16 |
2019-06-16 |
瑞士商諾華公司 |
組合療法
|
EP3713961A2
(de)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
|
AU2018382966A1
(en)
|
2017-12-14 |
2020-04-09 |
F. Hoffmann-La Roche Ag |
Use of a CEA CD3 bispecific antibody and a PD-1 axis binding antagonist in a dosage regime to treat cancer
|
JP2021508246A
(ja)
|
2017-12-21 |
2021-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規抗原結合部分の特異性試験のためのcar−t細胞アッセイ
|
EP3502140A1
(de)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
|
JP7394058B2
(ja)
|
2017-12-21 |
2023-12-07 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
|
BR112020011469A2
(pt)
|
2017-12-21 |
2020-11-24 |
F. Hoffmann-La Roche Ag |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
CN111542543B
(zh)
|
2017-12-28 |
2023-12-22 |
南京传奇生物科技有限公司 |
针对pd-l1的抗体及其变体
|
CN117050184A
(zh)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
JP7436365B2
(ja)
|
2017-12-29 |
2024-02-21 |
エフ. ホフマン-ラ ロシュ アーゲー |
抗vegf抗体及び使用の方法
|
CN111886246A
(zh)
|
2017-12-29 |
2020-11-03 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
JP7366908B2
(ja)
|
2018-01-15 |
2023-10-23 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Pd-1に対する単一ドメイン抗体及びその変異体
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
WO2019149715A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Stabilized immunoglobulin domains
|
CN111971301A
(zh)
|
2018-01-31 |
2020-11-20 |
艾莱克特有限责任公司 |
抗ms4a4a抗体及其使用方法
|
WO2019152660A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Lag3に結合する抗原結合部位を含む二重特異性抗体
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
CN111787947A
(zh)
|
2018-02-09 |
2020-10-16 |
豪夫迈·罗氏有限公司 |
用于肥大细胞介导的炎性疾病的治疗和诊断方法
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
EP3759491A1
(de)
|
2018-03-01 |
2021-01-06 |
H. Hoffnabb-La Roche Ag |
Spezifizitätstests für neuartige zielantigenbindende gruppen
|
TW202003561A
(zh)
|
2018-03-13 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
CA3092002A1
(en)
|
2018-03-13 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
CN112166123B
(zh)
|
2018-03-14 |
2022-09-30 |
北京轩义医药科技有限公司 |
抗紧密连接蛋白18.2抗体
|
MX2020009296A
(es)
|
2018-03-15 |
2020-11-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
|
US11292850B2
(en)
|
2018-03-21 |
2022-04-05 |
ALX Oncology Inc. |
Antibodies against signal-regulatory protein α and methods of use
|
WO2019191552A1
(en)
|
2018-03-29 |
2019-10-03 |
Genentech, Inc. |
Modulating lactogenic activity in mammalian cells
|
US11840568B2
(en)
|
2018-04-02 |
2023-12-12 |
Mab-Venture Biopharm Co., Ltd. |
Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof
|
CN112424601A
(zh)
|
2018-04-04 |
2021-02-26 |
豪夫迈·罗氏有限公司 |
检测癌症患者中肿瘤抗原的诊断性测定法
|
JP7394067B2
(ja)
|
2018-04-04 |
2023-12-07 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がん患者における腫瘍抗原を検出するための診断アッセイ
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
SG11202007961QA
(en)
|
2018-04-13 |
2020-09-29 |
Hoffmann La Roche |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
WO2019213384A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
CA3100007A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
CN112654635A
(zh)
|
2018-05-14 |
2021-04-13 |
狼人治疗公司 |
可活化细胞因子多肽及其使用方法
|
CN112166196A
(zh)
|
2018-05-18 |
2021-01-01 |
豪夫迈·罗氏有限公司 |
大核酸的靶向细胞内递送
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
BR112020023844A2
(pt)
|
2018-05-25 |
2021-04-13 |
Alector Llc |
Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
US20210238308A1
(en)
|
2018-06-04 |
2021-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
MA52764A
(fr)
|
2018-06-08 |
2021-04-28 |
Alector Llc |
Anticorps anti-siglec-7 et leurs méthodes d'utilisation
|
BR112020025048A2
(pt)
|
2018-06-13 |
2021-04-06 |
Novartis Ag |
Receptores de antígeno quimérico de bcma e usos dos mesmos
|
CN112654394A
(zh)
|
2018-06-19 |
2021-04-13 |
阿塔盖有限责任公司 |
针对补体成分5的抗体分子和其用途
|
MX2020014091A
(es)
|
2018-06-23 |
2021-05-27 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii.
|
TW202035444A
(zh)
|
2018-06-27 |
2020-10-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
CN112384532A
(zh)
|
2018-06-29 |
2021-02-19 |
艾利妥 |
抗SIRP-β1抗体及其使用方法
|
EP3818082A1
(de)
|
2018-07-04 |
2021-05-12 |
F. Hoffmann-La Roche AG |
Neuartige bispezifische agonistische 4-1bb-antigen-bindende moleküle
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
HUE061841T2
(hu)
|
2018-07-13 |
2023-08-28 |
Alector Llc |
Anti-sortilin antitestek és felhasználásuk módszerei
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
WO2020018879A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
CN112512597A
(zh)
|
2018-07-26 |
2021-03-16 |
大日本住友制药肿瘤公司 |
用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
|
CA3106535A1
(en)
|
2018-07-27 |
2020-01-30 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
US20220195045A1
(en)
|
2018-08-03 |
2022-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
AR115925A1
(es)
|
2018-08-08 |
2021-03-10 |
Genentech Inc |
Uso de derivados de triptófano y l-metionina para formulación de proteínas
|
JP6718560B1
(ja)
|
2018-08-10 |
2020-07-08 |
中外製薬株式会社 |
抗cd137抗原結合分子およびその使用
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
WO2020041360A1
(en)
|
2018-08-21 |
2020-02-27 |
Quidel Corporation |
Dbpa antibodies and uses thereof
|
CN112638944A
(zh)
|
2018-08-23 |
2021-04-09 |
西进公司 |
抗tigit抗体
|
CN113801229A
(zh)
|
2018-08-31 |
2021-12-17 |
艾利妥 |
抗cd33抗体及其使用方法
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
AR114732A1
(es)
|
2018-09-18 |
2020-10-07 |
Hoffmann La Roche |
Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
EP3856764A4
(de)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
Maskierte cytokin-polypeptide
|
CN112839957A
(zh)
|
2018-09-28 |
2021-05-25 |
协和麒麟株式会社 |
Il-36抗体及其用途
|
EP3861025A1
(de)
|
2018-10-01 |
2021-08-11 |
F. Hoffmann-La Roche AG |
Bispezifische antigenbindende moleküle mit dreiwertiger bindung an cd40
|
CN112955468A
(zh)
|
2018-10-01 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
包含抗fap克隆212的双特异性抗原结合分子
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
WO2020081767A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
EP3870235A1
(de)
|
2018-10-24 |
2021-09-01 |
F. Hoffmann-La Roche AG |
Konjugierte chemische abbauauslöser und verwendungsverfahren
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
CN113260626A
(zh)
|
2018-11-05 |
2021-08-13 |
豪夫迈·罗氏有限公司 |
在原核宿主细胞中产生双链蛋白质的方法
|
JP2022507253A
(ja)
|
2018-11-13 |
2022-01-18 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
チェックポイント分子に対する多重特異性結合性構築物およびその使用
|
EP3884276A2
(de)
|
2018-11-23 |
2021-09-29 |
Katholieke Universiteit Leuven |
Vorhersage einer behandlungsreaktion bei entzündlichen darmerkrankungen
|
AU2019391097A1
(en)
|
2018-12-04 |
2021-05-20 |
Sumitomo Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
MX2021006573A
(es)
|
2018-12-06 |
2021-07-15 |
Genentech Inc |
Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
|
CN113227119A
(zh)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
AU2019402163A1
(en)
|
2018-12-20 |
2021-07-08 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
CA3123377A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Extended low dose regimens for mdm2 inhibitors
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
CA3121804A1
(en)
|
2018-12-21 |
2020-06-25 |
Genentech, Inc. |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
WO2020132220A1
(en)
|
2018-12-21 |
2020-06-25 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
CR20210330A
(es)
|
2018-12-21 |
2021-07-20 |
Hoffmann La Roche |
ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
|
CN113286822A
(zh)
|
2018-12-21 |
2021-08-20 |
豪夫迈·罗氏有限公司 |
靶向肿瘤的超激动性cd28抗原结合分子
|
US11608376B2
(en)
|
2018-12-21 |
2023-03-21 |
Hoffmann-La Roche Inc. |
Tumor-targeted agonistic CD28 antigen binding molecules
|
EP3902832A2
(de)
|
2018-12-26 |
2021-11-03 |
Xilio Development, Inc. |
Anti-ctla4-antikörper und verfahren zur verwendung davon
|
CN113272327A
(zh)
|
2018-12-30 |
2021-08-17 |
豪夫迈·罗氏有限公司 |
抗兔cd19抗体及其使用方法
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
EP3915581A4
(de)
|
2019-01-24 |
2023-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Neuartige krebsantigene und antikörper dieser antigene
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
KR20210146290A
(ko)
|
2019-02-12 |
2021-12-03 |
스미토모 다이니폰 파마 온콜로지, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
MX2021009763A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
|
WO2020169698A1
(en)
|
2019-02-21 |
2020-08-27 |
F. Hoffmann-La Roche Ag |
Sensitization of cancer cells to tnf by bet inhibition
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
AU2020228383A1
(en)
|
2019-02-27 |
2021-09-23 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
|
EP3935385A1
(de)
|
2019-03-08 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Verfahren zur detektion und quantifizierung von membranassoziierten proteinen auf extrazellulären vesikeln
|
JP2022524537A
(ja)
|
2019-03-13 |
2022-05-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
脂質付加タンパク質性構造の調製のためのプロセス
|
KR20210141555A
(ko)
|
2019-03-14 |
2021-11-23 |
제넨테크, 인크. |
Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
US11712433B2
(en)
|
2019-03-22 |
2023-08-01 |
Sumitomo Pharma Oncology, Inc. |
Compositions comprising PKM2 modulators and methods of treatment using the same
|
CA3135430A1
(en)
|
2019-03-29 |
2020-10-08 |
Atarga, Llc |
Anti fgf23 antibody
|
WO2020208124A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using a cea cd3 bispecific antibody and a wnt signaling inhibitor
|
EP3952996A1
(de)
|
2019-04-12 |
2022-02-16 |
F. Hoffmann-La Roche AG |
Bispezifische antigenbindende moleküle mit lipocalinmuteinen
|
KR20220004087A
(ko)
|
2019-04-19 |
2022-01-11 |
추가이 세이야쿠 가부시키가이샤 |
항체 개변 부위 인식 키메라 수용체
|
CN114364703A
(zh)
|
2019-04-19 |
2022-04-15 |
豪夫迈·罗氏有限公司 |
抗mertk抗体及它们的使用方法
|
RU2734432C1
(ru)
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
AU2020270376A1
(en)
|
2019-05-03 |
2021-10-07 |
Genentech, Inc. |
Methods of treating cancer with an anti-PD-L1 antibody
|
SG11202112223XA
(en)
|
2019-05-10 |
2021-12-30 |
Takeda Pharmaceuticals Co |
Antibody drug conjugates
|
MX2021013825A
(es)
|
2019-05-14 |
2022-01-18 |
Genentech Inc |
Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular.
|
MX2021013766A
(es)
|
2019-05-14 |
2022-02-21 |
Werewolf Therapeutics Inc |
Restos de separacion y metodos de uso de los mismos.
|
WO2020232262A1
(en)
|
2019-05-16 |
2020-11-19 |
Procisedx Inc. |
Assay detection methods for vcam-1 and calprotectin
|
WO2020232295A1
(en)
|
2019-05-16 |
2020-11-19 |
Procisedx Inc. |
An assay method for the detection of vcam-1 and alpha-2-macroglobulin in blood
|
JP2022534227A
(ja)
|
2019-05-23 |
2022-07-28 |
プロサイセデクス インコーポレイティド |
ヒト血清アルブミン、ビタミンd、c反応性タンパク質、及び抗トランスグルタミナーゼ自己抗体の検出のためのアッセイ方法
|
TW202112799A
(zh)
|
2019-06-05 |
2021-04-01 |
美商建南德克公司 |
過載層析管柱之再生方法
|
JP2022535125A
(ja)
|
2019-06-06 |
2022-08-04 |
プロサイセデクス インコーポレイティド |
血中ヘモグロビンA1C(HbA1c)の検出
|
WO2020252066A1
(en)
|
2019-06-11 |
2020-12-17 |
Alector Llc |
Anti-sortilin antibodies for use in therapy
|
EP3990922A1
(de)
|
2019-06-25 |
2022-05-04 |
ProciseDx Inc. |
Nachweis von anti-tnf-alpha biologika und anti-wirkstoff-antikörpern
|
MX2021015888A
(es)
|
2019-06-26 |
2022-03-22 |
Hoffmann La Roche |
Fusión de un anticuerpo que se une a cea y 4-1bbl.
|
CN114531878A
(zh)
|
2019-06-27 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
新颖icos抗体及包含它们的肿瘤靶向抗原结合分子
|
US11865177B2
(en)
|
2019-06-28 |
2024-01-09 |
Genentech, Inc. |
Composition and methods for stabilizing liquid protein formulations
|
TW202115115A
(zh)
|
2019-07-02 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
免疫結合物
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
EP3998083A4
(de)
|
2019-07-12 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörper gegen mutationstyp fgfr3 und verwendung davon
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
BR112022000876A2
(pt)
|
2019-07-19 |
2022-04-26 |
Oncoresponse Inc |
Anticorpos imunomoduladores e métodos de uso destes
|
JP2022543551A
(ja)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Gprc5dに結合する抗体
|
PE20220487A1
(es)
|
2019-07-31 |
2022-04-04 |
Alector Llc |
Anticuerpos anti-ms4a4a y metodos de uso de los mismos
|
KR20220028035A
(ko)
|
2019-07-31 |
2022-03-08 |
에프. 호프만-라 로슈 아게 |
Gprc5d에 결합하는 항체
|
MX2022002963A
(es)
|
2019-09-12 |
2022-04-06 |
Genentech Inc |
Composiciones y metodos para tratar nefritis lupica.
|
TW202126698A
(zh)
|
2019-09-18 |
2021-07-16 |
美商建南德克公司 |
抗klk7抗體、抗klk5抗體、多重特異性抗klk5/klk7抗體、及使用方法
|
KR20220066295A
(ko)
|
2019-09-20 |
2022-05-24 |
제넨테크, 인크. |
항트립타제 항체의 투약
|
CN114829401A
(zh)
|
2019-09-27 |
2022-07-29 |
南京金斯瑞生物科技有限公司 |
抗vhh域抗体及其用途
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
MX2022004443A
(es)
|
2019-10-18 |
2022-05-02 |
Genentech Inc |
Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
MX2022004769A
(es)
|
2019-10-21 |
2022-05-16 |
Novartis Ag |
Inhibidores de tim-3 y sus usos.
|
BR112022008652A2
(pt)
|
2019-11-05 |
2022-07-19 |
Hoffmann La Roche |
Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção
|
EP4055388A1
(de)
|
2019-11-06 |
2022-09-14 |
Genentech, Inc. |
Diagnostische und therapeutische verfahren zur behandlung von hämatologischem krebs
|
MX2022006391A
(es)
|
2019-11-26 |
2022-06-24 |
Novartis Ag |
Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
|
EP3986937A1
(de)
|
2019-12-05 |
2022-04-27 |
Alector LLC |
Verfahren zur verwendung von anti-trem2-antikörpern
|
CN115066437A
(zh)
|
2019-12-12 |
2022-09-16 |
艾利妥 |
使用抗cd33抗体的方法
|
BR112022011570A2
(pt)
|
2019-12-13 |
2022-12-13 |
Alector Llc |
Anticorpos anti-mertk e métodos de uso dos mesmos
|
US11845799B2
(en)
|
2019-12-13 |
2023-12-19 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
PE20221282A1
(es)
|
2019-12-18 |
2022-09-05 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
CR20220334A
(es)
|
2019-12-23 |
2022-08-26 |
Genentech Inc |
Anticuerpos específicos de apolipoproteína l1 y métodos de uso
|
IL294226A
(en)
|
2019-12-27 |
2022-08-01 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibodies and their use
|
MX2022008214A
(es)
|
2020-01-09 |
2022-08-08 |
Hoffmann La Roche |
Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
IL293752A
(en)
|
2020-01-17 |
2022-08-01 |
Novartis Ag |
A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
US20230078601A1
(en)
|
2020-01-31 |
2023-03-16 |
The Cleveland Clinic Foundation |
Anti-mullerian hormone receptor 2 antibodies and methods of use
|
IL294859A
(en)
|
2020-01-31 |
2022-09-01 |
Genentech Inc |
Methods for induction of neoepitope-specific t cells with spindle-binding antagonist 1-pd and RNA vaccine
|
CA3167299A1
(en)
|
2020-02-10 |
2021-08-19 |
Shanghai Escugen Biotechnology Co., Ltd. |
Cldn18.2 antibody and use thereof
|
KR20220140786A
(ko)
|
2020-02-10 |
2022-10-18 |
상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 |
클라우딘18.2 항체 및 그것의 사용
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
CN115768794A
(zh)
|
2020-02-24 |
2023-03-07 |
艾利妥 |
抗trem2抗体的使用方法
|
CA3173737A1
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
BR112022018254A2
(pt)
|
2020-03-13 |
2022-10-25 |
Genentech Inc |
Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
|
CA3169626A1
(en)
|
2020-03-19 |
2021-09-23 |
Genentech, Inc. |
Isoform-selective anti-tgf-beta antibodies and methods of use
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
CN115867649A
(zh)
|
2020-03-24 |
2023-03-28 |
基因泰克公司 |
Tie2结合剂及其使用方法
|
WO2021195464A2
(en)
|
2020-03-26 |
2021-09-30 |
Genentech, Inc. |
Modified mammalian cells
|
BR112022017526A2
(pt)
|
2020-03-31 |
2022-10-18 |
Chugai Pharmaceutical Co Ltd |
Método para produzir moléculas de ligação de antígeno multiespecíficas
|
JP2023519962A
(ja)
|
2020-03-31 |
2023-05-15 |
アレクトル エルエルシー |
抗mertk抗体及びその使用方法
|
US20230107644A1
(en)
|
2020-04-01 |
2023-04-06 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
CA3172451A1
(en)
|
2020-04-03 |
2021-10-07 |
Robert Paul |
Methods of use of anti-trem2 antibodies
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック, インコーポレイテッド |
がんに対する治療方法及び診断方法
|
AU2021252156A1
(en)
|
2020-04-09 |
2022-11-03 |
Technische Universität München |
Targeted delivery of an inhibitor of miR-21 to macrophages for the treatment of pulmonary fibrosis
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
IL294451A
(en)
|
2020-04-15 |
2022-09-01 |
Hoffmann La Roche |
immune conjugates
|
TW202206111A
(zh)
|
2020-04-24 |
2022-02-16 |
美商建南德克公司 |
使用抗cd79b免疫結合物之方法
|
CA3178472A1
(en)
|
2020-04-24 |
2021-10-28 |
F. Hoffmann-La Roche Ag |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
US20230167198A1
(en)
|
2020-04-27 |
2023-06-01 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
WO2021222533A1
(en)
|
2020-04-30 |
2021-11-04 |
Procisedx Inc. |
Methods of detecting antibodies to sars-cov-2
|
TW202200212A
(zh)
|
2020-05-03 |
2022-01-01 |
中國大陸商聯寧(蘇州)生物製藥有限公司 |
包含抗-trop-2抗體之抗體藥物結合物
|
EP4149964A2
(de)
|
2020-05-15 |
2023-03-22 |
Apogenix AG |
Multispezifische immunmodulatoren
|
IL298668A
(en)
|
2020-05-29 |
2023-01-01 |
23Andme Inc |
Antibodies against cd200r1 and methods of using them
|
JP2023527918A
(ja)
|
2020-06-08 |
2023-06-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗hbv抗体及び使用方法
|
AU2021289738A1
(en)
|
2020-06-11 |
2022-12-15 |
Genentech, Inc. |
Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック, インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
EP4168118A1
(de)
|
2020-06-18 |
2023-04-26 |
Genentech, Inc. |
Behandlung mit anti-tigit-antikörpern und pd-1-achsen-bindenden antagonisten
|
CN115698084A
(zh)
|
2020-06-19 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
与cd3结合的抗体
|
AU2021291005A1
(en)
|
2020-06-19 |
2023-01-05 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3 and FolR1
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
IL296429A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Protease-activated t-cell bispecific antibodies
|
AU2021291011A1
(en)
|
2020-06-19 |
2023-01-05 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3 and CD19
|
US20230235040A1
(en)
|
2020-06-22 |
2023-07-27 |
Almirall, S.A. |
Anti-il-36 antibodies and methods of use thereof
|
JP2023530760A
(ja)
|
2020-06-23 |
2023-07-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Her2を標的とするアゴニストCD28抗原結合分子
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
EP4172192A1
(de)
|
2020-06-24 |
2023-05-03 |
Genentech, Inc. |
Apoptoseresistente zelllinien
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd3/抗cd28二重特異性抗原結合分子
|
AU2021303508A1
(en)
|
2020-07-10 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
TW202204895A
(zh)
|
2020-07-13 |
2022-02-01 |
美商建南德克公司 |
預測多肽免疫性的基於細胞之方法
|
JP2023534214A
(ja)
|
2020-07-16 |
2023-08-08 |
ノバルティス アーゲー |
抗ベータセルリン抗体、その断片、及び多重特異性結合分子
|
AU2021308653A1
(en)
|
2020-07-17 |
2023-02-16 |
Genentech, Inc. |
Anti-Notch2 antibodies and methods of use
|
AU2021312225A1
(en)
|
2020-07-21 |
2023-02-16 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation of BRM and methods thereof
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
EP4188549A1
(de)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroarylsubstituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dionderivate und verwendungen davon
|
WO2022031948A1
(en)
|
2020-08-07 |
2022-02-10 |
Genentech, Inc. |
T cell-based methods for predicting polypeptide immunogenicity
|
TW202227625A
(zh)
|
2020-08-28 |
2022-07-16 |
美商建南德克公司 |
宿主細胞蛋白質之CRISPR/Cas9多重剔除
|
EP4204020A1
(de)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Verfahren zur behandlung von psma-exprimierenden krebsarten
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
KR20230086690A
(ko)
|
2020-09-14 |
2023-06-15 |
아이크노스 사이언스 에스. 아. |
Il1rap에 결합하는 항체 및 이의 용도
|
EP4216998A1
(de)
|
2020-09-24 |
2023-08-02 |
F. Hoffmann-La Roche AG |
Vorbeugung oder abschwächung von t-zell-bispezifischen antikörpern in zusammenhang mit nebenwirkungen
|
KR20230082632A
(ko)
|
2020-10-05 |
2023-06-08 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Peg結合抗mertk抗體及其使用方法
|
AU2021363536A1
(en)
|
2020-10-20 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
|
JP2023548034A
(ja)
|
2020-10-22 |
2023-11-15 |
ヤンセン バイオテツク,インコーポレーテツド |
デルタ様リガンド3(dll3)抗原結合ドメインを含むタンパク質及びその使用
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
EP4237450A1
(de)
|
2020-10-30 |
2023-09-06 |
F. Hoffmann-La Roche AG |
Behandlung von krebs mit einem bispezifischen cea-cd3-antikörper und einem tgfbeta-signalisierungshemmer
|
CA3196191A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
AU2021374590A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
AR123997A1
(es)
|
2020-11-04 |
2023-02-01 |
Univ Rockefeller |
ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2
|
US20220162329A1
(en)
|
2020-11-04 |
2022-05-26 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Fc変異体
|
IL302402A
(en)
|
2020-11-08 |
2023-06-01 |
Seagen Inc |
Combined treatment
|
IL302390A
(en)
|
2020-11-09 |
2023-06-01 |
Takeda Pharmaceuticals Co |
Drug antibody conjugates
|
WO2022101120A1
(en)
|
2020-11-10 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
KR20230107617A
(ko)
|
2020-11-13 |
2023-07-17 |
노파르티스 아게 |
키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
|
US20240002483A1
(en)
|
2020-11-16 |
2024-01-04 |
Hoffmann-La Roche Inc. |
Fab high mannose glycoforms
|
JP2023549316A
(ja)
|
2020-11-16 |
2023-11-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Fapを標的としたcd40アゴニストとの併用療法
|
JP2023553399A
(ja)
|
2020-12-02 |
2023-12-21 |
アレクトル エルエルシー |
抗ソルチリン抗体の使用法
|
EP4255923A2
(de)
|
2020-12-04 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Ph-abhängige mutante interleukin-2-polypeptide
|
JP2023551983A
(ja)
|
2020-12-07 |
2023-12-13 |
ユーシービー バイオファルマ エスアールエル |
インターロイキン-22に対する抗体
|
AU2021395729A1
(en)
|
2020-12-07 |
2023-07-13 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
JP7326584B2
(ja)
|
2020-12-17 |
2023-08-15 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗hla-g抗体及びその使用
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
IL304067A
(en)
|
2021-01-06 |
2023-08-01 |
Hoffmann La Roche |
Combined treatment using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
|
EP4277705A1
(de)
|
2021-01-12 |
2023-11-22 |
F. Hoffmann-La Roche AG |
An krebszellen bindende geteilte antikörper und target-radionuklide an diese zellen
|
EP4277668A1
(de)
|
2021-01-13 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Kombinationstherapie
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
WO2022159349A1
(en)
|
2021-01-20 |
2022-07-28 |
Oncoresponse, Inc. |
Immunomodulatory antibodies and uses thereof
|
EP4281484A1
(de)
|
2021-01-22 |
2023-11-29 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2-konstrukte und verwendungen davon
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
EP4301467A1
(de)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Kombination von ctla4 und pd1/pdl1-antikörpern zur behandlung von krebs
|
CA3209364A1
(en)
|
2021-03-01 |
2022-09-09 |
Jennifer O'neil |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
JP2024509169A
(ja)
|
2021-03-03 |
2024-02-29 |
ソレント・セラピューティクス・インコーポレイテッド |
抗bcma抗体を含む抗体-薬物コンジュゲート
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
JP2024512002A
(ja)
|
2021-03-18 |
2024-03-18 |
アレクトル エルエルシー |
抗tmem106b抗体、及び、その使用方法
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
WO2022204274A1
(en)
|
2021-03-23 |
2022-09-29 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
GB202104104D0
(en)
|
2021-03-24 |
2021-05-05 |
Liliumx Ltd |
Platform and method
|
WO2022201122A1
(en)
|
2021-03-26 |
2022-09-29 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
CN117157312A
(zh)
|
2021-03-30 |
2023-12-01 |
豪夫迈·罗氏有限公司 |
蛋白酶活化的多肽
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
IL307556A
(en)
|
2021-04-09 |
2023-12-01 |
Seagen Inc |
Cancer treatment methods using antibodies against TIGIT
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
EP4326855A1
(de)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modifizierte säugerzellen
|
CN117222412A
(zh)
|
2021-04-23 |
2023-12-12 |
豪夫迈·罗氏有限公司 |
Nk细胞接合剂相关的不良反应的预防或减轻
|
AU2021443863A1
(en)
|
2021-04-30 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
KR20240004694A
(ko)
|
2021-05-03 |
2024-01-11 |
유씨비 바이오파마 에스알엘 |
항체
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
IL308351A
(en)
|
2021-05-12 |
2024-01-01 |
Genentech Inc |
Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
|
US20220389097A1
(en)
|
2021-05-14 |
2022-12-08 |
Genentech Inc. |
Agonists of TREM2
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
EP4155321A1
(de)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2-antikörper und verwendungen davon
|
BR112023025738A2
(pt)
|
2021-06-09 |
2024-02-27 |
Hoffmann La Roche |
Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
IL309115A
(en)
|
2021-06-25 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies
|
BR112023023480A2
(pt)
|
2021-06-25 |
2024-01-30 |
Chugai Pharmaceutical Co Ltd |
Uso de anticorpo anti-ctla-4
|
BR112023026966A2
(pt)
|
2021-07-02 |
2024-03-12 |
Hoffmann La Roche |
Métodos para tratar um indivíduo com melanoma, para alcançar uma resposta clínica, para tratar um indivíduo com linfoma não hodgkin, para tratar uma população de indivíduos com linfoma não hodgkin e para tratar um indivíduo com câncer colorretal metastático
|
US20230049152A1
(en)
|
2021-07-14 |
2023-02-16 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
WO2023001884A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CN117715936A
(zh)
|
2021-07-28 |
2024-03-15 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的方法和组合物
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
IL310662A
(en)
|
2021-08-23 |
2024-04-01 |
Immunitas Therapeutics Inc |
Anti-CD161 antibodies and their uses
|
IL310382A
(en)
|
2021-08-27 |
2024-03-01 |
Genentech Inc |
Methods for treating tau pathologies
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
WO2023062050A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023073225A1
(en)
|
2021-11-01 |
2023-05-04 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and a 4-1bb (cd137) agonist
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
WO2023088876A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
Multi-specific immune modulators
|
WO2023088889A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
CD137 ligands
|
WO2023091887A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
US20230312724A1
(en)
|
2021-12-01 |
2023-10-05 |
Kadmon Corporation, Llc |
B7-H4 Antibodies and Anti-B7-H4 Antibody/IL-15 Fusion Proteins
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023110788A1
(en)
|
2021-12-14 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using a hla-a2/mage-a4 x cd3 bispecific antibody and a 4-1bb (cd137) agonist
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
TW202340248A
(zh)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
促效性ltbr抗體及包含其之雙特異性抗體
|
WO2023131901A1
(en)
|
2022-01-07 |
2023-07-13 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗notch2抗體及結合物及其使用方法
|
WO2023147329A1
(en)
|
2022-01-26 |
2023-08-03 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation and methods thereof
|
WO2023147328A1
(en)
|
2022-01-26 |
2023-08-03 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
TW202400636A
(zh)
|
2022-03-11 |
2024-01-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(一)
|
TW202346355A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(二)
|
WO2023170295A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
TW202402790A
(zh)
|
2022-03-25 |
2024-01-16 |
英商梅迪繆思有限公司 |
減少呼吸系統感染之方法
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2023192622A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
US20230416412A1
(en)
|
2022-05-31 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024015993A1
(en)
|
2022-07-15 |
2024-01-18 |
Fibrogen, Inc. |
Modified anti-galectin-9 antibody and uses thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020579A1
(en)
|
2022-07-22 |
2024-01-25 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024040216A2
(en)
|
2022-08-19 |
2024-02-22 |
Fibrogen, Inc. |
Anti-ccr8 antibodies and uses thereof
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024056861A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for stimulating nk cells and use thereof
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024069180A2
(en)
|
2022-09-28 |
2024-04-04 |
LiliumX Ltd. |
Multivalent proteins and screening methods
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|